BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60:197-209. [PMID: 23993913 DOI: 10.1016/j.jhep.2013.07.044] [Cited by in Crossref: 398] [Cited by in F6Publishing: 354] [Article Influence: 49.8] [Reference Citation Analysis]
Number Citing Articles
1 Fukui H, Wiest R. Changes of Intestinal Functions in Liver Cirrhosis. Inflamm Intest Dis. 2016;1:24-40. [PMID: 29922655 DOI: 10.1159/000444436].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Capalbo O, Giuliani S, Ferrero-Fernández A, Casciato P, Musso CG. Kidney-liver pathophysiological crosstalk: its characteristics and importance. Int Urol Nephrol 2019;51:2203-7. [PMID: 31549285 DOI: 10.1007/s11255-019-02288-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Matloff RG, Arnon R. The Kidney in Pediatric Liver Disease. Curr Gastroenterol Rep 2015;17. [DOI: 10.1007/s11894-015-0457-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
4 Stengel S, Quickert S, Lutz P, Ibidapo-Obe O, Steube A, Köse-Vogel N, Yarbakht M, Reuken PA, Busch M, Brandt A, Bergheim I, Deshmukh SD, Stallmach A, Bruns T. Peritoneal Level of CD206 Associates With Mortality and an Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and Spontaneous Bacterial Peritonitis. Gastroenterology 2020;158:1745-61. [PMID: 31982413 DOI: 10.1053/j.gastro.2020.01.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
5 Liu R, Li X, Huang Z, Zhao D, Ganesh BS, Lai G, Pandak WM, Hylemon PB, Bajaj JS, Sanyal AJ, Zhou H. C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice. Hepatology 2018;67:1441-57. [PMID: 28926118 DOI: 10.1002/hep.29540] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
6 Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021;75 Suppl 1:S67-81. [PMID: 34039493 DOI: 10.1016/j.jhep.2020.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Lv XY, Ding HG, Zheng JF, Fan CL, Li L. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World J Gastroenterol 2020; 26(2): 199-218 [PMID: 31988585 DOI: 10.3748/wjg.v26.i2.199] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
8 Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol 2021;27:437-45. [PMID: 33504138 DOI: 10.3350/cmh.2020.0329] [Reference Citation Analysis]
9 D’amico G, Perricone G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter? Curr Hepatology Rep 2019;18:144-56. [DOI: 10.1007/s11901-019-00473-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Martinsen TC, Fossmark R, Waldum HL. The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid. Int J Mol Sci 2019;20:E6031. [PMID: 31795477 DOI: 10.3390/ijms20236031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
11 Hu R, Zhou F, Zhou T, Shen J, Wang Z, Zhao Z, Qin A, Tang BZ. Specific discrimination of gram-positive bacteria and direct visualization of its infection towards mammalian cells by a DPAN-based AIEgen. Biomaterials 2018;187:47-54. [DOI: 10.1016/j.biomaterials.2018.09.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 14.0] [Reference Citation Analysis]
12 Weil D, Di Martino V, Mourey G, Biichle S, Renaudin A, Laheurte C, Cypriani B, Delabrousse E, Grandclément E, Thévenot T, Saas P; the MICROCIR Study Group. Small Annexin V-Positive Platelet-Derived Microvesicles Affect Prognosis in Cirrhosis: A Longitudinal Study. Clin Transl Gastroenterol 2021;12:e00333. [PMID: 33908373 DOI: 10.14309/ctg.0000000000000333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Li FC, Fan YC, Li YK, Wang K. Plasma diamine oxidase level predicts 6-month readmission for patients with hepatitis B virus-related decompensated cirrhosis. Virol J 2019;16:115. [PMID: 31533748 DOI: 10.1186/s12985-019-1219-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Mohandas S, Vairappan B. Pregnane X receptor activation by its natural ligand Ginkgolide-A improves tight junction proteins expression and attenuates bacterial translocation in cirrhosis. Chem Biol Interact. 2020;315:108891. [PMID: 31697926 DOI: 10.1016/j.cbi.2019.108891] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
15 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
16 Nischalke HD, Fischer J, Klüners A, Matz-Soja M, Krämer B, Langhans B, Goeser F, Soyka M, Stickel F, Spengler U, Nattermann J, Strassburg CP, Berg T, Lutz P. A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. Liver Int 2021;41:2139-48. [PMID: 34051061 DOI: 10.1111/liv.14980] [Reference Citation Analysis]
17 Hackstein CP, Assmus LM, Welz M, Klein S, Schwandt T, Schultze J, Förster I, Gondorf F, Beyer M, Kroy D, Kurts C, Trebicka J, Kastenmüller W, Knolle PA, Abdullah Z. Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis. Gut 2017;66:507-18. [PMID: 27432540 DOI: 10.1136/gutjnl-2015-311224] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
18 Cao X, Liu M, Wang P, Liu DY. Intestinal dendritic cells change in number in fulminant hepatic failure. World J Gastroenterol 2015; 21(16): 4883-4893 [PMID: 25945001 DOI: 10.3748/wjg.v21.i16.4883] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
19 Hoenigl M, Lin J, Finkelman M, Zhang Y, Karris MY, Letendre SL, Ellis RJ, Burke L, Richard B, Gaufin T, Isnard S, Routy JP, Gianella S. Glucan rich nutrition does not increase gut translocation of beta-glucan. Mycoses 2021;64:24-9. [PMID: 32780885 DOI: 10.1111/myc.13161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
20 Voiosu AM, Bălănescu P, Daha I, Smarandache B, Rădoi A, Mateescu RB, Băicuş CR, Voiosu TA. The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy. Rom J Intern Med 2018;56:182-92. [PMID: 29453929 DOI: 10.2478/rjim-2018-0007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Hendrikx T, Schnabl B. Antimicrobial proteins: intestinal guards to protect against liver disease. J Gastroenterol 2019;54:209-17. [PMID: 30392013 DOI: 10.1007/s00535-018-1521-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
22 Van der Merwe S, Chokshi S, Bernsmeier C, Albillos A. The multifactorial mechanisms of bacterial infection in decompensated cirrhosis. J Hepatol 2021;75 Suppl 1:S82-S100. [PMID: 34039494 DOI: 10.1016/j.jhep.2020.11.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ibidapo-Obe O, Stengel S, Köse-Vogel N, Quickert S, Reuken PA, Busch M, Bauer M, Stallmach A, Bruns T. Mucosal-Associated Invariant T Cells Redistribute to the Peritoneal Cavity During Spontaneous Bacterial Peritonitis and Contribute to Peritoneal Inflammation. Cell Mol Gastroenterol Hepatol 2020;9:661-77. [PMID: 31954178 DOI: 10.1016/j.jcmgh.2020.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
24 Skinner C, Thompson AJ, Thursz MR, Marchesi JR, Vergis N. Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. Therap Adv Gastroenterol 2020;13:1756284820942616. [PMID: 33149761 DOI: 10.1177/1756284820942616] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Dirchwolf M, Ruf AE. Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis. World J Hepatol 2015; 7(16): 1974-1981 [PMID: 26261687 DOI: 10.4254/wjh.v7.i16.1974] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
26 Sánchez E, Nieto JC, Vidal S, Santiago A, Martinez X, Sancho FJ, Sancho-Bru P, Mirelis B, Corominola H, Juárez C, Manichanh C, Guarner C, Soriano G. Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride. Sci Rep 2017;7:45712. [PMID: 28368023 DOI: 10.1038/srep45712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
27 Caparrós E, Juanola O, Gómez-Hurtado I, Puig-Kroger A, Piñero P, Zapater P, Linares R, Tarín F, Martínez-López S, Gracia-Sancho J, González-Navajas JM, Francés R. Liver Sinusoidal Endothelial Cells Contribute to Hepatic Antigen-Presenting Cell Function and Th17 Expansion in Cirrhosis. Cells 2020;9:E1227. [PMID: 32429209 DOI: 10.3390/cells9051227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wang N, Yao W, Ma R, Ren F. The efficacy of a multistrain probiotic on cognitive function and risk of falls in patients with cirrhosis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25535. [PMID: 33879696 DOI: 10.1097/MD.0000000000025535] [Reference Citation Analysis]
29 Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis. Hepatology 2016;64:908-22. [PMID: 27081787 DOI: 10.1002/hep.28598] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 8.4] [Reference Citation Analysis]
30 Alexopoulou A, Vasilieva L, Agiasotelli D, Siranidi K, Pouriki S, Tsiriga A, Toutouza M, Dourakis SP. Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia. World J Gastroenterol 2016; 22(15): 4049-4056 [PMID: 27099449 DOI: 10.3748/wjg.v22.i15.4049] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
31 Sanduzzi Zamparelli M, Rocco A, Compare D, Nardone G. The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. United European Gastroenterol J. 2017;5:944-953. [PMID: 29163959 DOI: 10.1177/2050640617705576] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
32 Kaliannan K. Compromise of α-Defensin Function in Liver Cirrhosis Facilitates the Toxic Relationship Between Gut Permeability and Endotoxemia. Dig Dis Sci 2018;63:2492-4. [PMID: 30008088 DOI: 10.1007/s10620-018-5197-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tu B, Zhang YN, Bi JF, Xu Z, Zhao P, Shi L, Zhang X, Yang G, Qin EQ. Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis. World J Gastroenterol 2020; 26(29): 4316-4326 [PMID: 32848336 DOI: 10.3748/wjg.v26.i29.4316] [Reference Citation Analysis]
34 Potgieter M, Bester J, Kell DB, Pretorius E. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev 2015;39:567-91. [PMID: 25940667 DOI: 10.1093/femsre/fuv013] [Cited by in Crossref: 215] [Cited by in F6Publishing: 197] [Article Influence: 35.8] [Reference Citation Analysis]
35 Santiago A, Sanchez E, Clark A, Pozuelo M, Calvo M, Yañez F, Sarrabayrouse G, Perea L, Vidal S, Gallardo A, Guarner C, Soriano G, Manichanh C. Sequential Changes in the Mesenteric Lymph Node Microbiome and Immune Response during Cirrhosis Induction in Rats. mSystems 2019;4:e00278-18. [PMID: 30801032 DOI: 10.1128/mSystems.00278-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
36 Jain V, Alexander EC, Burford C, Verma A, Dhawan A. Gut Microbiome: A Potential Modifiable Risk Factor in Biliary Atresia. J Pediatr Gastroenterol Nutr 2021;72:184-93. [PMID: 33427793 DOI: 10.1097/MPG.0000000000002973] [Reference Citation Analysis]
37 Engelmann C, Becker C, Boldt A, Herta T, Boehlig A, Splith K, Schmelzle M, Mueller N, Krohn S, Tautenhahn HM, Bartels M, Sack U, Berg T. Ascites' neutrophil function is significantly impaired in patients with decompensated cirrhosis but can be restored by autologous plasma incubation. Sci Rep. 2016;6:37926. [PMID: 27917877 DOI: 10.1038/srep37926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
38 Kimer N, Gudmann NS, Pedersen JS, Møller S, Nielsen MJ, Leeming DJ, Karsdal MA, Møller HJ, Bendtsen F, Grønbæk H. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. PLoS One 2018;13:e0203200. [PMID: 30183743 DOI: 10.1371/journal.pone.0203200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Gustot T, Fernandez J, Szabo G, Albillos A, Louvet A, Jalan R, Moreau R, Moreno C. Sepsis in alcohol-related liver disease. J Hepatol. 2017;67:1031-1050. [PMID: 28647569 DOI: 10.1016/j.jhep.2017.06.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 11.3] [Reference Citation Analysis]
40 Møller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Dig Dis Sci 2015;60:3209-25. [DOI: 10.1007/s10620-015-3752-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
41 Lefebvre E, Gottwald M, Lasseter K, Chang W, Willett M, Smith PF, Somasunderam A, Utay NS. Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment. Clin Transl Sci. 2016;9:139-148. [PMID: 27169903 DOI: 10.1111/cts.12397] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
42 Lu YA, Tu KH, Lee CC, Wu PW, Chang CJ, Tian YC, Yang CW, Chu PH. Prognostic impact of peritonitis in hemodialysis patients: A national-wide longitudinal study in Taiwan. PLoS One 2017;12:e0173710. [PMID: 28301536 DOI: 10.1371/journal.pone.0173710] [Reference Citation Analysis]
43 Cheng Y, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, Ghabril M, Orman E, Sashidhar S, Rogers N, Xu H, Khoruts A, Vaughn B, Kao D, Wong K, Cammarota G, Ianiro G, Dhere T, Kraft CS, Mehta N, Woodworth MH, Allegretti JR, Nativ L, Marcus J, El-nachef N, Fischer M. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clinical Gastroenterology and Hepatology 2021;19:1627-34. [DOI: 10.1016/j.cgh.2020.06.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Chen Y, Guo J, Shi D, Fang D, Chen C, Li L. Ascitic Bacterial Composition Is Associated With Clinical Outcomes in Cirrhotic Patients With Culture-Negative and Non-neutrocytic Ascites. Front Cell Infect Microbiol 2018;8:420. [PMID: 30555804 DOI: 10.3389/fcimb.2018.00420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
45 Bitto N, Liguori E, La Mura V. Coagulation, Microenvironment and Liver Fibrosis. Cells. 2018;7:pii: E85. [PMID: 30042349 DOI: 10.3390/cells7080085] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
46 Solé C, Pose E, Solà E, Ginès P. Hepatorenal syndrome in the era of acute kidney injury.Liver Int. 2018;38:1891-1901. [PMID: 29845739 DOI: 10.1111/liv.13893] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
47 Wan S, Huang C, Wang A, Zhu X. Ursolic acid improves the bacterial community mapping of the intestinal tract in liver fibrosis mice. PeerJ 2020;8:e9050. [PMID: 32355580 DOI: 10.7717/peerj.9050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Albillos A, Lario M, Álvarez-mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology 2014;61:1385-96. [DOI: 10.1016/j.jhep.2014.08.010] [Cited by in Crossref: 470] [Cited by in F6Publishing: 433] [Article Influence: 67.1] [Reference Citation Analysis]
49 Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, Fernández J, To U, García-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016;2:16041. [PMID: 27277335 DOI: 10.1038/nrdp.2016.41] [Cited by in Crossref: 159] [Cited by in F6Publishing: 146] [Article Influence: 31.8] [Reference Citation Analysis]
50 Gambato M, Villanueva A, Abraldes JG, Altamirano J, Forns X. Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. J Hepatol 2015;63:753-62. [PMID: 26095181 DOI: 10.1016/j.jhep.2015.06.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
51 Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71:811-822. [PMID: 31302175 DOI: 10.1016/j.jhep.2019.07.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 38.5] [Reference Citation Analysis]
52 Artigas A, Wernerman J, Arroyo V, Vincent JL, Levy M. Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis. J Crit Care 2016;33:62-70. [PMID: 26831575 DOI: 10.1016/j.jcrc.2015.12.019] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]
53 Li N, Hua J. Immune cells in liver regeneration. Oncotarget. 2017;8:3628-3639. [PMID: 27690296 DOI: 10.18632/oncotarget.12275] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
54 Melliez H, Mary-Krause M, Guiguet M, Carrieri P, Abgrall S, Enel P, Gallien S, Duval X, Duvivier C, Pavie J, Siguier M, Freire-Maresca A, Tattevin P, Costagliola D. Risk of Severe Bacterial Infection in People Living Human Immunodeficiency Virus Infection in the Combined Antiretroviral Therapy Era. J Infect Dis 2020;222:765-76. [PMID: 32253435 DOI: 10.1093/infdis/jiaa154] [Reference Citation Analysis]
55 Kimer N, Wiese S, Mo S, Møller S, Bendtsen F. Advances in the treatment of portal hypertension in cirrhosis. Expert Rev Gastroenterol Hepatol 2016;10:961-9. [PMID: 26982499 DOI: 10.1586/17474124.2016.1166952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Wang C, Li Q, Ren J. Microbiota-Immune Interaction in the Pathogenesis of Gut-Derived Infection. Front Immunol. 2019;10:1873. [PMID: 31456801 DOI: 10.3389/fimmu.2019.01873] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
57 Plaza-Díaz J, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, Álvarez-Mercado AI. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. Int J Mol Sci 2020;21:E8351. [PMID: 33171747 DOI: 10.3390/ijms21218351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
58 Barbuti RC, Schiavon LL, Oliveira CP, Alvares-DA-Silva MR, Sassaki LY, Passos MDCF, Farias AQ, Barros LL, Barreto BP, Albuquerque GBML, Alves AM, Navarro-Rodriguez T, Bittencourt PL. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). Arq Gastroenterol 2020;57:381-98. [PMID: 33331485 DOI: 10.1590/S0004-2803.202000000-72] [Reference Citation Analysis]
59 Singal AK, Shah VH. Current trials and novel therapeutic targets for alcoholic hepatitis. J Hepatol 2019;70:305-13. [PMID: 30658731 DOI: 10.1016/j.jhep.2018.10.026] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 32.0] [Reference Citation Analysis]
60 Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M. Immune dysfunction in cirrhosis. World J Gastroenterol 2014; 20(10): 2564-2577 [PMID: 24627592 DOI: 10.3748/wjg.v20.i10.2564] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 79] [Article Influence: 13.9] [Reference Citation Analysis]
61 Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017;179:142-157. [PMID: 28546081 DOI: 10.1016/j.pharmthera.2017.05.011] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 24.3] [Reference Citation Analysis]
62 Sung H, Kim SW, Hong M, Suk KT. Microbiota-based treatments in alcoholic liver disease. World J Gastroenterol 2016; 22(29): 6673-6682 [PMID: 27547010 DOI: 10.3748/wjg.v22.i29.6673] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
63 Chen Z, Han S, Zhou D, Zhou S, Jia G. Effects of oral exposure to titanium dioxide nanoparticles on gut microbiota and gut-associated metabolism in vivo. Nanoscale 2019;11:22398-412. [DOI: 10.1039/c9nr07580a] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 20.0] [Reference Citation Analysis]
64 Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front Immunol 2019;10:293. [PMID: 30873165 DOI: 10.3389/fimmu.2019.00293] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 19.5] [Reference Citation Analysis]
65 Chen S, Li X, Li M, Mei Q, Huang J, Wu Z, Zhang L. Mucosal expression of defensin-5, soluble phospholipase A2 and lysozyme in the intestine in a rat model of acute liver failure and its relationship to intestinal bacterial translocation. Gastroenterol Hepatol 2020;43:293-300. [PMID: 32278502 DOI: 10.1016/j.gastrohep.2020.01.004] [Reference Citation Analysis]
66 Vilela EG, Pinheiro CDS, Saturnino SF, Gomes CGO, Nascimento VCD, Andrade MVM. EVALUATION OF THE BEHAVIOR OF LEVELS OF HMGB1 AND IL6 AS PREDICTORS OF INFECTION, ACUTE KIDNEY INJURY AND MORTALITY IN CIRRHOTIC PATIENTS WITH VARICEAL BLEEDING. Arq Gastroenterol 2018;55:338-42. [PMID: 30785515 DOI: 10.1590/S0004-2803.201800000-75] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
67 Subasi O, Yildiz SY, Yuksel A, Coskun M, Turgut HT, Yildiz E. The effect of immunonutrition on bacterial translocation after Pringle maneuverer in rats. Prz Gastroenterol 2019;14:178-82. [PMID: 31649788 DOI: 10.5114/pg.2019.88166] [Reference Citation Analysis]
68 Durand F, Graupera I, Ginès P, Olson JC, Nadim MK. Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. Am J Kidney Dis 2016;67:318-28. [PMID: 26500178 DOI: 10.1053/j.ajkd.2015.09.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
69 Pradhan-Sundd T, Monga SP. Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology. Gene Expr 2019;19:69-87. [PMID: 30646969 DOI: 10.3727/105221619X15469715711907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
70 Kimer N, Pedersen JS, Busk TM, Gluud LL, Hobolth L, Krag A, Møller S, Bendtsen F; Copenhagen Rifaximin (CoRif) Study Group. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology 2017;65:592-603. [PMID: 27775818 DOI: 10.1002/hep.28898] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
71 Zhao J, Ran M, Yang T, Chen L, Ji P, Xu X, Zhang L, Sun S, Liu X, Zhou S, Zhou L, Zhang J. Bicyclol Alleviates Signs of BDL-Induced Cholestasis by Regulating Bile Acids and Autophagy-Mediated HMGB1/p62/Nrf2 Pathway. Front Pharmacol 2021;12:686502. [PMID: 34366845 DOI: 10.3389/fphar.2021.686502] [Reference Citation Analysis]
72 Song DS. [Spontaneous Bacterial Peritonitis]. Korean J Gastroenterol 2018;72:56-63. [PMID: 30145857 DOI: 10.4166/kjg.2018.72.2.56] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
73 Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol. 2017;67:1084-1103. [PMID: 28526488 DOI: 10.1016/j.jhep.2017.05.007] [Cited by in Crossref: 163] [Cited by in F6Publishing: 153] [Article Influence: 40.8] [Reference Citation Analysis]
74 Møller S, Kimer N, Barløse M, Bendtsen F. Pathophysiological-based treatments of complications of cirrhosis. Scand J Gastroenterol 2020;55:383-94. [PMID: 32233873 DOI: 10.1080/00365521.2020.1744709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Han SH, Suk KT, Kim DJ, Kim MY, Baik SK, Kim YD, Cheon GJ, Choi DH, Ham YL, Shin DH. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol. 2015;27:1300-1306. [PMID: 26302024 DOI: 10.1097/meg.0000000000000458] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
76 Kimer N, Pedersen JS, Tavenier J, Christensen JE, Busk TM, Hobolth L, Krag A, Al-Soud WA, Mortensen MS, Sørensen SJ, Møller S, Bendtsen F; members of the CoRif study group. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. J Gastroenterol Hepatol 2018;33:307-14. [PMID: 28671712 DOI: 10.1111/jgh.13852] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
77 Moreau N, Wittebole X, Fleury Y, Forget P, Laterre PF, Castanares-Zapatero D. Neutrophil-to-Lymphocyte Ratio Predicts Death in Acute-on-Chronic Liver Failure Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study. Shock. 2018;49:385-392. [PMID: 28930918 DOI: 10.1097/shk.0000000000000993] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
78 Portela-Cidade JP, Borges-Canha M, Leite-Moreira AF, Pimentel-Nunes P. Systematic Review of the Relation Between Intestinal Microbiota and Toll-Like Receptors in the Metabolic Syndrome: What Do We Know So Far? GE Port J Gastroenterol 2015;22:240-58. [PMID: 28868416 DOI: 10.1016/j.jpge.2015.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Haderer M, Neubert P, Rinner E, Scholtis A, Broncy L, Gschwendtner H, Kandulski A, Pavel V, Mehrl A, Brochhausen C, Schlosser S, Gülow K, Kunst C, Müller M. Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases. Gut 2021:gutjnl-2020-321663. [PMID: 33707230 DOI: 10.1136/gutjnl-2020-321663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Weston CJ, Zimmermann HW, Adams DH. The Role of Myeloid-Derived Cells in the Progression of Liver Disease. Front Immunol 2019;10:893. [PMID: 31068952 DOI: 10.3389/fimmu.2019.00893] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
81 Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, Triantos CK, Thomopoulos KC. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications. World J Hepatol 2015; 7(17): 2058-2068 [PMID: 26301048 DOI: 10.4254/wjh.v7.i17.2058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
82 Wu F, Li H, Zhang H, Liao Y, Ren H, Wu J, Zheng D. Phosphorylated‑myosin light chain mediates the destruction of small intestinal epithelial tight junctions in mice with acute liver failure. Mol Med Rep 2021;23:392. [PMID: 33760163 DOI: 10.3892/mmr.2021.12031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Irvine KM, Banh X, Gadd VL, Wojcik KK, Ariffin JK, Jose S, Lukowski S, Baillie GJ, Sweet MJ, Powell EE. CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites. JCI Insight 2016;1:e86914. [PMID: 27699269 DOI: 10.1172/jci.insight.86914] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
84 Graupera I, Coll M, Pose E, Elia C, Piano S, Solà E, Blaya D, Huelin P, Solé C, Moreira R, de Prada G, Fabrellas N, Juanola A, Morales-Ruiz M, Sancho-Bru P, Villanueva C, Ginès P. Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. Sci Rep 2017;7:1829. [PMID: 28500294 DOI: 10.1038/s41598-017-01709-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
85 Piano S, Angeli P. Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation? Clin Liver Dis 2021;25:357-72. [PMID: 33838855 DOI: 10.1016/j.cld.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Matuchansky C. Bacterial translocation in liver cirrhosis: site and role in fibrogenesis. J Hepatol 2014;61:709-10. [PMID: 24768829 DOI: 10.1016/j.jhep.2014.04.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
87 Wang C, Li Q, Tang C, Zhao X, He Q, Tang X, Ren J. Characterization of the blood and neutrophil-specific microbiomes and exploration of potential bacterial biomarkers for sepsis in surgical patients. Immun Inflamm Dis 2021. [PMID: 34288545 DOI: 10.1002/iid3.483] [Reference Citation Analysis]
88 Tripathi DM, Vilaseca M, Lafoz E, Garcia-Calderó H, Viegas Haute G, Fernández-Iglesias A, Rodrigues de Oliveira J, García-Pagán JC, Bosch J, Gracia-Sancho J. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology 2018;155:1564-77. [PMID: 30055171 DOI: 10.1053/j.gastro.2018.07.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
89 Papp M, Tornai T, Vitalis Z, Tornai I, Tornai D, Dinya T, Sumegi A, Antal-Szalmas P. Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis. World J Gastroenterol 2016; 22(41): 9172-9185 [PMID: 27895404 DOI: 10.3748/wjg.v22.i41.9172] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
90 Zuccaro V, Lombardi A, Asperges E, Sacchi P, Marone P, Gazzola A, Arcaini L, Bruno R. The Possible Role of Gut Microbiota and Microbial Translocation Profiling During Chemo-Free Treatment of Lymphoid Malignancies. Int J Mol Sci 2019;20:E1748. [PMID: 30970593 DOI: 10.3390/ijms20071748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Sakamaki A, Kamimura K, Yokoo T, Osaki A, Yoshikawa S, Arao Y, Setsu T, Kamimura H, Waguri N, Takeuchi M, Funakoshi K, Terai S. The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan. Medicine (Baltimore) 2021;100:e26902. [PMID: 34397919 DOI: 10.1097/MD.0000000000026902] [Reference Citation Analysis]
92 Chen Z, Xie Y, Zhou F, Zhang B, Wu J, Yang L, Xu S, Stedtfeld R, Chen Q, Liu J, Zhang X, Xu H, Ren J. Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease. Front Microbiol 2020;11:383. [PMID: 32265857 DOI: 10.3389/fmicb.2020.00383] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
93 Oikonomou T, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E. Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol 2018; 24(34): 3813-3820 [PMID: 30228776 DOI: 10.3748/wjg.v24.i34.3813] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
94 Yousif MM, Sadek AMEM, Farrag HA, Selim FO, Hamed EF, Salama RI. Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis. Intern Emerg Med 2019;14:753-61. [PMID: 30706253 DOI: 10.1007/s11739-019-02042-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
95 Okimoto S, Tashiro H, Iwako H, Kuroda S, Kobayashi T, Hinoi T, Ohdan H. Antithrombin attenuates the progression of hepatocellular carcinoma by regulating neutrophil/interleukin-8 signaling. Hepatol Res 2020;50:1284-96. [PMID: 32893935 DOI: 10.1111/hepr.13558] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Miozzo SAS, John JA, Appel-da-Silva MC, Dossin IA, Tovo CV, Mattos AA. Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis. World J Hepatol 2017; 9(35): 1278-1285 [PMID: 29290909 DOI: 10.4254/wjh.v9.i35.1278] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
97 Vega-magaña N, Delgado-rizo V, García-benavides L, Toro-arreola SD, Segura-ortega J, Morales ASMZ, Zepeda-nuño JS, Escarra-senmarti M, Gutiérrez-franco J, Haramati J, Bueno-topete MR. Bacterial Translocation Is Linked to Increased Intestinal IFN-γ, IL-4, IL-17, and mucin-2 in Cholestatic Rats. Annals of Hepatology 2018;17:318-29. [DOI: 10.5604/01.3001.0010.8663] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
98 Shenoda B, Boselli J. Vascular syndromes in liver cirrhosis. Clin J Gastroenterol 2019;12:387-97. [PMID: 30980261 DOI: 10.1007/s12328-019-00956-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
99 Weil D, Pais de Barros JP, Mourey G, Laheurte C, Cypriani B, Badet N, Delabrousse E, Grandclément E, Di Martino V, Saas P, Lagrost L, Thévenot T. Circulating levels of 3-hydroxymyristate, a direct quantification of endotoxaemia in noninfected cirrhotic patients. Liver Int 2019;39:106-14. [PMID: 29931819 DOI: 10.1111/liv.13916] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
100 Thanda Han MA, Pyrsopoulos N. Emerging Therapies for Alcoholic Hepatitis. Clin Liver Dis 2021;25:603-24. [PMID: 34229843 DOI: 10.1016/j.cld.2021.03.006] [Reference Citation Analysis]
101 Rafiei R, Bemanian M, Rafiei F, Bahrami M, Fooladi L, Ebrahimi G, Hemmat A, Torabi Z. Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. Rom J Intern Med 2018;56:85-9. [PMID: 29101772 DOI: 10.1515/rjim-2017-0042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
102 Tan-Garcia A, Wai LE, Zheng D, Ceccarello E, Jo J, Banu N, Khakpoor A, Chia A, Tham CYL, Tan AT. Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease. J Hepatol. 2017;67:490-500. [PMID: 28483682 DOI: 10.1016/j.jhep.2017.04.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
103 Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T, Koda Y, Chu PS, Taniki N, Yamaguchi A, Kanamori M, Kamada N, Hattori M, Ashida H, Sakamoto M, Atarashi K, Narushima S, Yoshimura A, Honda K, Sato T, Kanai T. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019;4:492-503. [PMID: 30643240 DOI: 10.1038/s41564-018-0333-1] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 48.5] [Reference Citation Analysis]
104 Wang Y, Fu L, Ren J, Yu Z, Chen T, Sun F. Identifying Group-Specific Sequences for Microbial Communities Using Long k-mer Sequence Signatures. Front Microbiol 2018;9:872. [PMID: 29774017 DOI: 10.3389/fmicb.2018.00872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
105 Moghadamrad S, Mccoy KD, Geuking MB, Sägesser H, Kirundi J, Macpherson AJ, De Gottardi A. Attenuated portal hypertension in germ-free mice: Function of bacterial flora on the development of mesenteric lymphatic and blood vessels: HEPATOLOGY, Vol. XX, NO. X, 2015. Hepatology 2015;61:1685-95. [DOI: 10.1002/hep.27698] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
106 Moratalla A, Caparrós E, Juanola O, Portune K, Puig-Kröger A, Estrada-Capetillo L, Bellot P, Gómez-Hurtado I, Piñero P, Zapater P, González-Navajas JM, Such J, Sanz Y, Francés R. Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis. J Hepatol 2016;64:135-45. [PMID: 26334579 DOI: 10.1016/j.jhep.2015.08.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
107 Ørntoft NW, Blé M, Baiges A, Ferrusquia J, Hernández-Gea V, Turon F, Magaz M, Møller S, Møller HJ, Garcia-Pagan JC, Gronbaek H. Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension. Front Physiol 2021;12:649668. [PMID: 34177608 DOI: 10.3389/fphys.2021.649668] [Reference Citation Analysis]
108 Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577. [PMID: 31622696 DOI: 10.1016/j.jhep.2019.10.003] [Cited by in Crossref: 141] [Cited by in F6Publishing: 151] [Article Influence: 70.5] [Reference Citation Analysis]
109 Patel VC, Williams R. Antimicrobial resistance in chronic liver disease. Hepatol Int. 2020;14:24-34. [PMID: 31797303 DOI: 10.1007/s12072-019-10004-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
110 Wang M, Lv J, Zhang X, Chen P, Zhao M, Zhang H. Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy. Kidney Int Rep 2020;5:165-72. [PMID: 32043030 DOI: 10.1016/j.ekir.2019.10.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
111 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513-1524. [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020] [Cited by in Crossref: 487] [Cited by in F6Publishing: 468] [Article Influence: 69.6] [Reference Citation Analysis]
112 Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…. Liver Int 2021;41:1734-43. [PMID: 34051060 DOI: 10.1111/liv.14977] [Reference Citation Analysis]
113 Zhou X, Li J, Guo J, Geng B, Ji W, Zhao Q, Li J, Liu X, Liu J, Guo Z, Cai W, Ma Y, Ren D, Miao J, Chen S, Zhang Z, Chen J, Zhong J, Liu W, Zou M, Li Y, Cai J. Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction. Microbiome 2018;6:66. [PMID: 29615110 DOI: 10.1186/s40168-018-0441-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 20.0] [Reference Citation Analysis]
114 Bolte FJ, O'Keefe AC, Webb LM, Serti E, Rivera E, Liang TJ, Ghany M, Rehermann B. Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation. Gastroenterology. 2017;153:1392-1403.e2. [PMID: 28780074 DOI: 10.1053/j.gastro.2017.07.043] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
115 Mücke MM, Mayer A, Kessel J, Mücke VT, Bon D, Schwarzkopf K, Rüschenbaum S, Queck A, Göttig S, Vermehren A, Weiler N, Welker MW, Reinheimer C, Hogardt M, Vermehren J, Herrmann E, Kempf VAJ, Zeuzem S, Lange CM. Quinolone and Multidrug Resistance Predicts Failure of Antibiotic Prophylaxis of Spontaneous Bacterial Peritonitis. Clin Infect Dis 2020;70:1916-24. [PMID: 31228250 DOI: 10.1093/cid/ciz540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
116 Mani I, Alexopoulou A, Vasilieva L, Hadziyannis E, Agiasotelli D, Bei M, Alexopoulos T, Dourakis SP. Human beta-defensin-1 is a highly predictive marker of mortality in patients with acute-on-chronic liver failure. Liver Int 2019;39:299-306. [PMID: 30261128 DOI: 10.1111/liv.13977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Fernández-Montero JV, Barreiro P, de Mendoza C, Labarga P, Soriano V. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat. 2016;23:47-52. [PMID: 26390144 DOI: 10.1111/jvh.12447] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
118 Møller S, Bendtsen F. Complications of cirrhosis. A 50 years flashback. Scand J Gastroenterol. 2015;50:763-780. [PMID: 25881709 DOI: 10.3109/00365521.2015.1021709] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
119 Rha MS, Han JW, Koh JY, Lee HS, Kim JH, Cho K, Kim SI, Kim MS, Lee JG, Park SH, Joo DJ, Park JY, Shin EC. Impaired antibacterial response of liver sinusoidal Vγ9+Vδ2+ T cells in patients with chronic liver disease. Gut 2021:gutjnl-2020-322182. [PMID: 33472894 DOI: 10.1136/gutjnl-2020-322182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Anand AC. Nutrition and Muscle in Cirrhosis. J Clin Exp Hepatol. 2017;7:340-357. [PMID: 29234200 DOI: 10.1016/j.jceh.2017.11.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 13.5] [Reference Citation Analysis]
121 Smorodin E, Sergeyev B, Kurtenkov O, Kuznetsova T, Geller J. IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment. Dis Markers 2018;2018:4639805. [PMID: 30627223 DOI: 10.1155/2018/4639805] [Reference Citation Analysis]
122 Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 2018;38:570-80. [PMID: 28921803 DOI: 10.1111/liv.13589] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 19.0] [Reference Citation Analysis]
123 Egerod Israelsen M, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol 2015;30:236-43. [PMID: 25160511 DOI: 10.1111/jgh.12709] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
124 Lehmann JM, Claus K, Jansen C, Pohlmann A, Schierwagen R, Meyer C, Thomas D, Manekeller S, Claria J, Strassburg CP, Trautwein C, Wasmuth HE, Berres ML, Trebicka J. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. Liver Int 2018;38:875-84. [PMID: 29105936 DOI: 10.1111/liv.13610] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
125 Yu J, Shi X, Ma J, Chen R, Dong S, Lu S, Wu J, Yan C, Wu J, Zheng S, Li L, Xu X, Cao H. C-Reactive Protein Is an Independent Predictor of 30-Day Bacterial Infection Post-Liver Transplantation. Biomolecules 2021;11:1195. [PMID: 34439862 DOI: 10.3390/biom11081195] [Reference Citation Analysis]
126 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Feder S, Haberl EM, Spirk M, Weiss TS, Wiest R, Buechler C. Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients. Clin Exp Med 2020;20:289-97. [PMID: 32078718 DOI: 10.1007/s10238-020-00617-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
128 Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, Mantovani A. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016;64:1416-1427. [PMID: 26921689 DOI: 10.1016/j.jhep.2016.02.029] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 16.4] [Reference Citation Analysis]
129 Agraz-Cibrián JM, Delgado-Rizo V, Segura-Ortega JE, Maldonado-Gómez HA, Zambrano-Zaragoza JF, Durán-Avelar MJ, Vibanco-Perez N, Fafutis-Morris M. Impaired neutrophil extracellular traps and inflammatory responses in the peritoneal fluid of patients with liver cirrhosis. Scand J Immunol 2018;88:e12714. [PMID: 30226638 DOI: 10.1111/sji.12714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
130 Chakaroun RM, Massier L, Kovacs P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders? Nutrients 2020;12:E1082. [PMID: 32295104 DOI: 10.3390/nu12041082] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 44.0] [Reference Citation Analysis]
131 Li Q, Wang J, Lu M, Qiu Y, Lu H. Acute-on-Chronic Liver Failure From Chronic-Hepatitis-B, Who Is the Behind Scenes. Front Microbiol 2020;11:583423. [PMID: 33365018 DOI: 10.3389/fmicb.2020.583423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015;148:30-36. [PMID: 25447847 DOI: 10.1053/j.gastro.2014.10.042] [Cited by in Crossref: 314] [Cited by in F6Publishing: 304] [Article Influence: 44.9] [Reference Citation Analysis]
133 Verhoeven F, Weil-Verhoeven D, Prati C, Martino VD, Thevenot T, Wendling D. Safety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis. Semin Arthritis Rheum 2020;50:544-8. [PMID: 32446022 DOI: 10.1016/j.semarthrit.2020.03.013] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
134 Aller MA, Arias N, Blanco-Rivero J, Arias J. Metabolism in Acute-On-Chronic Liver Failure: The Solution More than the Problem. Arch Med Res 2019;50:271-84. [PMID: 31593852 DOI: 10.1016/j.arcmed.2019.09.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Chen Y, Ji F, Guo J, Shi D, Fang D, Li L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep. 2016;6:34055. [PMID: 27687977 DOI: 10.1038/srep34055] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 17.2] [Reference Citation Analysis]
136 Piotrowski D, Boroń-Kaczmarska A. Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment. Adv Med Sci 2017;62:345-56. [PMID: 28514703 DOI: 10.1016/j.advms.2016.11.009] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
137 Pradhan-Sundd T, Gudapati S, Kaminski TW, Ragni MV. Exploring the Complex Role of Coagulation Factor VIII in Chronic Liver Disease. Cell Mol Gastroenterol Hepatol 2021;12:1061-72. [PMID: 33705963 DOI: 10.1016/j.jcmgh.2021.02.014] [Reference Citation Analysis]
138 Tao X, Wang N, Qin W. Gut Microbiota and Hepatocellular Carcinoma. Gastrointest Tumors. 2015;2:33-40. [PMID: 26673641 DOI: 10.1159/000380895] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
139 Gupta K, Bhurwal A, Law C, Ventre S, Minacapelli CD, Kabaria S, Li Y, Tait C, Catalano C, Rustgi VK. Acute kidney injury and hepatorenal syndrome in cirrhosis. World J Gastroenterol 2021; 27(26): 3984-4003 [PMID: 34326609 DOI: 10.3748/wjg.v27.i26.3984] [Reference Citation Analysis]
140 Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients 2021;13:1018. [PMID: 33801133 DOI: 10.3390/nu13031018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Orci LA, Lacotte S, Delaune V, Slits F, Oldani G, Lazarevic V, Rossetti C, Rubbia-Brandt L, Morel P, Toso C. Effects of the gut-liver axis on ischaemia-mediated hepatocellular carcinoma recurrence in the mouse liver. J Hepatol. 2018;68:978-985. [PMID: 29331341 DOI: 10.1016/j.jhep.2017.12.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
142 Nicoletti A, Ponziani FR, Biolato M, Valenza V, Marrone G, Sganga G, Gasbarrini A, Miele L, Grieco A. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol 2019; 25(33): 4814-4834 [PMID: 31543676 DOI: 10.3748/wjg.v25.i33.4814] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
143 Chen D, Le TH, Shahidipour H, Read SA, Ahlenstiel G. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression. Cells 2019;8:E1324. [PMID: 31717860 DOI: 10.3390/cells8111324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
144 Voulgaris TA, Karagiannakis D, Hadziyannis E, Manolakopoulos S, Karamanolis GP, Papatheodoridis G, Vlachogiannakos J. Serum zonulin levels in patients with liver cirrhosis: Prognostic implications. World J Hepatol 2021; 13(10): 1394-1404 [DOI: 10.4254/wjh.v13.i10.1394] [Reference Citation Analysis]
145 Waghray A, Waghray N, Khallafi H, Menon KV. Vaccinating Adult Patients with Cirrhosis: Trends over a Decade in the United States. Gastroenterol Res Pract 2016;2016:5795712. [PMID: 27239192 DOI: 10.1155/2016/5795712] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
146 Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int 2018;12:122-34. [DOI: 10.1007/s12072-017-9815-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
147 Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C, Squizzato A. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. J Transl Int Med 2020;8:220-36. [PMID: 33511049 DOI: 10.2478/jtim-2020-0035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Enderes J, Teschke J, Manekeller S, Vilz TO, Kalff JC, Glowka TR. Chronic Liver Disease Increases Mortality Following Pancreatoduodenectomy. J Clin Med 2021;10:2521. [PMID: 34200183 DOI: 10.3390/jcm10112521] [Reference Citation Analysis]
149 Syue LS, Chen PL, Wu CJ, Lee NY, Lee CC, Li CW, Li MC, Tang HJ, Hsueh PR, Ko WC. Monomicrobial Aeromonas and Vibrio bacteremia in cirrhotic adults in southern Taiwan: Similarities and differences. J Microbiol Immunol Infect 2016;49:509-15. [PMID: 25070280 DOI: 10.1016/j.jmii.2014.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
150 Maurice JB, Garvey L, Tsochatzis EA, Wiltshire M, Cooke G, Guppy N, McDonald J, Marchesi J, Nelson M, Kelleher P, Goldin R, Thursz M, Lemoine M. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. AIDS 2019;33:805-14. [PMID: 30882489 DOI: 10.1097/QAD.0000000000002133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
151 Reichert MC, Ripoll C, Casper M, Greinert R, Vandieken E, Grünhage F, Appenrodt B, Zipprich A, Lammert F. Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis. Clin Transl Gastroenterol 2019;10:e00002. [PMID: 30702490 DOI: 10.14309/ctg.0000000000000002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
152 Wen S, Li X, Ling Y, Chen S, Deng Q, Yang L, Li Y, Shen J, Qiu Y, Zhan Y, Lai H, Zhang X, Ke Z, Huang W. HMGB1-associated necroptosis and Kupffer cells M1 polarization underlies remote liver injury induced by intestinal ischemia/reperfusion in rats. FASEB J 2020;34:4384-402. [PMID: 31961020 DOI: 10.1096/fj.201900817R] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
153 Dirchwolf M, Podhorzer A, Marino M, Shulman C, Cartier M, Zunino M, Paz S, Muñoz A, Bocassi A, Gimenez J, Di Pietro L, Romero G, Fainboim H, Fainboim L. Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity. Cytokine 2016;77:14-25. [DOI: 10.1016/j.cyto.2015.10.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
154 Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol 2015; 21(41): 11597-11608 [PMID: 26556989 DOI: 10.3748/wjg.v21.i41.11597] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
155 Zhao H, Luo Y, Wu Z, Zhou Y, Guo D, Wang H, Chen X. Hepatic lipid metabolism and oxidative stress responses of grass carp (Ctenopharyngodon idella) fed diets of two different lipid levels against Aeromonas hydrophila infection. Aquaculture 2019;509:149-58. [DOI: 10.1016/j.aquaculture.2019.05.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
156 Iebba V, Guerrieri F, Di Gregorio V, Levrero M, Gagliardi A, Santangelo F, Sobolev AP, Circi S, Giannelli V, Mannina L, Schippa S, Merli M. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Sci Rep 2018;8:8210. [PMID: 29844325 DOI: 10.1038/s41598-018-26509-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
157 Ojeda-Yuren AS, Cerda-Reyes E, Herrero-Maceda MR, Castro-Narro G, Piano S. An Integrated Review of the Hepatorenal Syndrome. Ann Hepatol 2021;22:100236. [PMID: 32846202 DOI: 10.1016/j.aohep.2020.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Wang PF, Yao DH, Hu YY, Li Y. Vitamin D Improves Intestinal Barrier Function in Cirrhosis Rats by Upregulating Heme Oxygenase-1 Expression. Biomol Ther (Seoul) 2019;27:222-30. [PMID: 30173501 DOI: 10.4062/biomolther.2018.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
159 Ren W, Wang X, Zhang A, Li C, Chen G, Ge X, Pan K, Dong J. Selective bowel decontamination improves the survival of 90% hepatectomy in rats. Journal of Surgical Research 2015;195:454-64. [DOI: 10.1016/j.jss.2015.01.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
160 Sánchez E, Nieto JC, Boullosa A, Vidal S, Sancho FJ, Rossi G, Sancho-Bru P, Oms R, Mirelis B, Juárez C. VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver Int. 2015;35:735-745. [PMID: 24750552 DOI: 10.1111/liv.12566] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
161 Liu Y, Cavallaro PM, Kim BM, Liu T, Wang H, Kühn F, Adiliaghdam F, Liu E, Vasan R, Samarbafzadeh E, Farber MZ, Li J, Xu M, Mohad V, Choi M, Hodin RA. A role for intestinal alkaline phosphatase in preventing liver fibrosis. Theranostics 2021;11:14-26. [PMID: 33391458 DOI: 10.7150/thno.48468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Vogt A, Reuken PA, Stengel S, Stallmach A, Bruns T. Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study. World J Gastroenterol 2016; 22(11): 3275-3284 [PMID: 27004006 DOI: 10.3748/wjg.v22.i11.3275] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
163 La Mura V, Pasarín M, Rodriguez-Vilarrupla A, García-Pagán JC, Bosch J, Abraldes JG. Liver sinusoidal endothelial dysfunction after LPS administration: a role for inducible-nitric oxide synthase. J Hepatol. 2014;61:1321-1327. [PMID: 25038487 DOI: 10.1016/j.jhep.2014.07.014] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
164 Juanola A, Solé C, Toapanta D, Ginès P, Solà E. Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. Clin Liver Dis 2021;25:441-60. [PMID: 33838860 DOI: 10.1016/j.cld.2021.01.011] [Reference Citation Analysis]
165 Agiasotelli D, Alexopoulou A, Vasilieva L, Hadziyannis E, Goukos D, Daikos GL, Dourakis SP. High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis. Liver Int. 2017;37:576-582. [PMID: 27712029 DOI: 10.1111/liv.13264] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
166 Patidar KR, Xu C, Shamseddeen H, Cheng YW, Ghabril MS, Mukthinuthalapati VVPK, Fricker ZP, Akinyeye S, Nephew LD, Desai AP, Anderson M, El-Achkar TM, Chalasani NP, Orman ES. Development and Validation of a Model to Predict Acute Kidney Injury in Hospitalized Patients With Cirrhosis. Clin Transl Gastroenterol 2019;10:e00075. [PMID: 31478958 DOI: 10.14309/ctg.0000000000000075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
167 Tornai D, Vitalis Z, Jonas A, Janka T, Foldi I, Tornai T, Sipeki N, Csillag A, Balogh B, Sumegi A, Foldesi R, Papp M, Antal-Szalmas P. Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality. Clin Res Hepatol Gastroenterol 2021;45:101579. [PMID: 33773436 DOI: 10.1016/j.clinre.2020.11.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
168 Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol 2015;1:275-84. [PMID: 26090511 DOI: 10.1016/j.jcmgh.2015.04.003] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 15.5] [Reference Citation Analysis]
169 Yokoyama K, Tsuchiya N, Yamauchi R, Miyayama T, Uchida Y, Shibata K, Fukuda H, Umeda K, Takata K, Tanaka T, Inomata S, Morihara D, Takeyama Y, Shakado S, Sakisaka S, Hirai F. Exploratory Research on the Relationship between Human Gut Microbiota and Portal Hypertension. Intern Med 2020;59:2089-94. [PMID: 32879200 DOI: 10.2169/internalmedicine.4628-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Mankal PK, Kotler DP. From wasting to obesity, changes in nutritional concerns in HIV/AIDS. Endocrinol Metab Clin North Am 2014;43:647-63. [PMID: 25169559 DOI: 10.1016/j.ecl.2014.05.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
171 Solé C, Pose E, Solà E. Editorial: macrophage activation markers predict prognosis and decompensation in patients with cirrhosis-linking gut permeability, inflammation and cirrhosis progression. Aliment Pharmacol Ther 2018;47:851-3. [PMID: 29446139 DOI: 10.1111/apt.14523] [Reference Citation Analysis]
172 Mendoza YP, Rodrigues SG, Bosch J, Berzigotti A. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. Digestive and Liver Disease 2020;52:958-65. [DOI: 10.1016/j.dld.2020.06.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
173 Lutz P, Nischalke HD, Strassburg CP, Spengler U. Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol 2015; 7(3): 304-314 [PMID: 25848460 DOI: 10.4254/wjh.v7.i3.304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
174 Møller S, Krag A, Bendtsen F. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int 2014;34:1153-63. [DOI: 10.1111/liv.12549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
175 Stutchfield BM, Bodingbauer MW, Adair A, Wakelin S, Schindl M, Forbes SJ, Wigmore SJ. Quantifying changes in innate immune function following liver transplantation for chronic liver disease. HPB (Oxford) 2019;21:1322-6. [PMID: 30850189 DOI: 10.1016/j.hpb.2019.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21(43): 12322-12333 [PMID: 26604640 DOI: 10.3748/wjg.v21.i43.12322] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
177 Ferstl P, Trebicka J. Acute Decompensation and Acute-on-Chronic Liver Failure. Clin Liver Dis 2021;25:419-30. [PMID: 33838858 DOI: 10.1016/j.cld.2021.01.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, Kudo M, Thimme R, Park J, Sharma R. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. Aliment Pharmacol Ther 2017;45:1146-55. [DOI: 10.1111/apt.13977] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
179 Luo M, Guo JY, Cao WK. Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. World J Gastroenterol 2015; 21(41): 11815-11824 [PMID: 26557005 DOI: 10.3748/wjg.v21.i41.11815] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
180 Zhu J, Qiu J, Chen K, Wang W, Zheng S. Tea polyphenols and Levofloxacin alleviate the lung injury of hepatopulmonary syndrome in common bile duct ligation rats through Endotoxin -TNF signaling. Biomed Pharmacother 2021;137:111263. [PMID: 33516071 DOI: 10.1016/j.biopha.2021.111263] [Reference Citation Analysis]
181 Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, Bauer DJM, Paternostro R, Schwabl P, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut 2021;70:1758-67. [PMID: 33199442 DOI: 10.1136/gutjnl-2020-322712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
182 Lingiah VA, Pyrsopoulos NT. Bacterial Infections in Cirrhotic Patients in a Tertiary Care Hospital. J Clin Transl Hepatol 2021;9:32-9. [PMID: 33604253 DOI: 10.14218/JCTH.2020.00076] [Reference Citation Analysis]
183 Gaslightwala I, Diehl DL. Bacteremia and sepsis after radiofrequency ablation of gastric antral vascular ectasia. Gastrointest Endosc 2014;79:873-4. [PMID: 24721631 DOI: 10.1016/j.gie.2014.01.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
184 Carvalho MVH, Kroll PC, Kroll RTM, Carvalho VN. Cirrhotic cardiomyopathy: the liver affects the heart. Braz J Med Biol Res 2019;52:e7809. [PMID: 30785477 DOI: 10.1590/1414-431X20187809] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
185 D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68:563-576. [PMID: 29111320 DOI: 10.1016/j.jhep.2017.10.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 97] [Article Influence: 29.0] [Reference Citation Analysis]
186 Liu H, Zhu P, Nie C, Ye Q, Gao Y, Liu H, Pang G, Han T. The value of ascitic neutrophil gelatinase-associated lipocalin in decompensated liver cirrhosis with spontaneous bacterial peritonitis. J Clin Lab Anal 2020;34:e23247. [PMID: 32100329 DOI: 10.1002/jcla.23247] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Bruns T, Zimmermann HW, Stallmach A. Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol 2014; 20(10): 2542-2554 [PMID: 24627590 DOI: 10.3748/wjg.v20.i10.2542] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
188 Arroyo V, Moreau R. Tying up PGE2 with albumin to relieve immunosuppression in cirrhosis. Nat Med. 2014;20:467-469. [PMID: 24804750 DOI: 10.1038/nm.3553] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
189 Karthikeyan A, Mohan P, Chinnakali P, Vairappan B. Elevated systemic zonula occludens 1 is positively correlated with inflammation in cirrhosis. Clin Chim Acta. 2018;480:193-198. [PMID: 29458051 DOI: 10.1016/j.cca.2018.02.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
190 Jauregi-Miguel A. The tight junction and the epithelial barrier in coeliac disease. Int Rev Cell Mol Biol 2021;358:105-32. [PMID: 33707052 DOI: 10.1016/bs.ircmb.2020.09.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
191 Fiore M, Gentile I, Maraolo AE, Leone S, Simeon V, Chiodini P, Pace MC, Gustot T, Taccone FS. Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis: . European Journal of Gastroenterology & Hepatology 2018;30:329-36. [DOI: 10.1097/meg.0000000000001057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
192 Kalambokis GN, Baltayiannis G, Christodoulou D. von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis. World J Gastroenterol 2016; 22(19): 4786-4788 [PMID: 27217711 DOI: 10.3748/wjg.v22.i19.4786] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
193 Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol 2016; 8(6): 307-321 [PMID: 26962397 DOI: 10.4254/wjh.v8.i6.307] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 19.4] [Reference Citation Analysis]
194 Juanola O, Ferrusquía-Acosta J, García-Villalba R, Zapater P, Magaz M, Marín A, Olivas P, Baiges A, Bellot P, Turon F, Hernández-Gea V, González-Navajas JM, Tomás-Barberán FA, García-Pagán JC, Francés R. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. FASEB J 2019;33:11595-605. [PMID: 31345057 DOI: 10.1096/fj.201901327R] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 11.5] [Reference Citation Analysis]
195 Jagarlamudi N, Wong F. Acute kidney injury: prediction, prognostication and optimisation for liver transplant. Hepatol Int 2020;14:167-79. [DOI: 10.1007/s12072-020-10018-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
196 Zhong W, Zhou Z. Sealing the Leaky Gut Represents a Beneficial Mechanism of Zinc Intervention for Alcoholic Liver Disease. Dietary Interventions in Gastrointestinal Diseases. Elsevier; 2019. pp. 91-106. [DOI: 10.1016/b978-0-12-814468-8.00008-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Berzigotti A, Saran U, Dufour JF. Physical activity and liver diseases. Hepatology. 2016;63:1026-1040. [PMID: 26313307 DOI: 10.1002/hep.28132] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 14.0] [Reference Citation Analysis]
198 Rackayová V, Flatt E, Braissant O, Grosse J, Capobianco D, Mastromarino P, McMillin M, DeMorrow S, McLin VA, Cudalbu C. Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease. Sci Rep 2021;11:2269. [PMID: 33500487 DOI: 10.1038/s41598-021-81871-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
199 Hibi A, Mizuguchi K, Yoneyama A, Kasugai T, Kamiya K, Kamiya K, Ito C, Kominato S, Miura T, Koyama K. Severe refractory TAFRO syndrome requiring continuous renal replacement therapy complicated with Trichosporon asahii infection in the lungs and myocardial infarction: an autopsy case report and literature review. Ren Replace Ther 2018;4:16. [PMID: 34171004 DOI: 10.1186/s41100-018-0157-8] [Reference Citation Analysis]
200 Haneche F, Brocard A, Garioud A, Cadranel JF. [Spontaneous bacterial peritonitis with listeria monocytogenes leading to a cirrhosis discovery]. Presse Med 2017;46:332-4. [PMID: 28017475 DOI: 10.1016/j.lpm.2016.11.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
201 Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers 2018;4:23. [PMID: 30213943 DOI: 10.1038/s41572-018-0022-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 18.7] [Reference Citation Analysis]
202 Quigley EM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol. 2014;30:141-146. [PMID: 24406476 DOI: 10.1097/mog.0000000000000040] [Cited by in Crossref: 50] [Cited by in F6Publishing: 19] [Article Influence: 7.1] [Reference Citation Analysis]
203 Alferink LJM, Oey RC, Hansen BE, Polak WG, van Buuren HR, de Man RA, Schurink CAM, Metselaar HJ. The impact of infections on delisting patients from the liver transplantation waiting list. Transpl Int 2017;30:807-16. [PMID: 28403563 DOI: 10.1111/tri.12965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
204 Engelmann C, Berg T. Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure. Visc Med. 2018;34:261-268. [PMID: 30345283 DOI: 10.1159/000491107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
205 Korf H, du Plessis J, van Pelt J, De Groote S, Cassiman D, Verbeke L, Ghesquière B, Fendt SM, Bird MJ, Talebi A, Van Haele M, Feio-Azevedo R, Meelberghs L, Roskams T, Mookerjee RP, Mehta G, Jalan R, Gustot T, Laleman W, Nevens F, van der Merwe SW. Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity. Gut 2019;68:1872-83. [PMID: 30580251 DOI: 10.1136/gutjnl-2018-316888] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
206 Yan K, Garcia-Tsao G. Novel prevention strategies for bacterial infections in cirrhosis. Expert Opin Pharmacother. 2016;17:689-701. [PMID: 26799197 DOI: 10.1517/14656566.2016.1145663] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
207 Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U. Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 2014; 20(45): 16795-16810 [PMID: 25492994 DOI: 10.3748/wjg.v20.i45.16795] [Cited by in CrossRef: 123] [Cited by in F6Publishing: 104] [Article Influence: 17.6] [Reference Citation Analysis]
208 Goel NJ, Abdullah KG, Choudhri OA, Kung DK, Lucas TH, Chen HI. The Effect of Underlying Liver Disease on Perioperative Outcomes Following Craniotomy for Tumor: An American College of Surgeons National Quality Improvement Program Analysis. World Neurosurgery 2018;115:e85-96. [DOI: 10.1016/j.wneu.2018.03.183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
209 Shi H, Lv L, Cao H, Lu H, Zhou N, Yang J, Jiang H, Dong H, Hu X, Yu W, Jiang X, Zheng B, Li L. Bacterial translocation aggravates CCl4-induced liver cirrhosis by regulating CD4+ T cells in rats. Sci Rep 2017;7:40516. [PMID: 28134306 DOI: 10.1038/srep40516] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
210 Grüngreiff K, Reinhold D, Wedemeyer H. The role of zinc in liver cirrhosis. Annals of Hepatology 2016;15:7-16. [DOI: 10.5604/16652681.1184191] [Cited by in Crossref: 64] [Cited by in F6Publishing: 49] [Article Influence: 12.8] [Reference Citation Analysis]
211 Kalambokis GN, Oikonomou A, Christou L, Kolaitis NI, Tsianos EV, Christodoulou D, Baltayiannis G. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. J Hepatol 2016;65:921-8. [PMID: 27297911 DOI: 10.1016/j.jhep.2016.06.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
212 Barroso FAL, de Jesus LCL, de Castro CP, Batista VL, Ferreira Ê, Fernandes RS, de Barros ALB, Leclerq SY, Azevedo V, Mancha-Agresti P, Drumond MM. Intake of Lactobacillus delbrueckii (pExu:hsp65) Prevents the Inflammation and the Disorganization of the Intestinal Mucosa in a Mouse Model of Mucositis. Microorganisms 2021;9:E107. [PMID: 33466324 DOI: 10.3390/microorganisms9010107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Zou Y, Cai Y, Lu D, Zhou Y, Yao Q, Zhang S. MicroRNA-146a-5p attenuates liver fibrosis by suppressing profibrogenic effects of TGFβ1 and lipopolysaccharide. Cell Signal 2017;39:1-8. [PMID: 28739486 DOI: 10.1016/j.cellsig.2017.07.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
214 Fernández J, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C, Reverter E, Martínez J, Saliba F, Jalan R, Welzel T, Pavesi M, Hernández-tejero M, Ginès P, Arroyo V. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 2018;67:1870-80. [DOI: 10.1136/gutjnl-2017-314240] [Cited by in Crossref: 177] [Cited by in F6Publishing: 162] [Article Influence: 44.3] [Reference Citation Analysis]
215 Mohandas S, Vairappan B. Ginkgolide-A attenuates bacterial translocation through activating PXR and improving antimicrobial peptide Reg 3A in experimental cirrhosis. Life Sciences 2020;257:118111. [DOI: 10.1016/j.lfs.2020.118111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
216 Luo M, Liu H, Hu S, Bai F. Potential targeted therapies for the inflammatory pathogenesis of hepatic encephalopathy. Clinics and Research in Hepatology and Gastroenterology 2015;39:665-73. [DOI: 10.1016/j.clinre.2015.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
217 Appenrodt B, Lammert F. Renal Failure in Patients with Liver Cirrhosis: Novel Classifications, Biomarkers, Treatment. Visc Med 2018;34:246-52. [PMID: 30345281 DOI: 10.1159/000492587] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
218 Czigany Z, Hata K, Lai W, Schwandt T, Yamamoto Y, Uemoto S, Tolba RH. A Dual Protective Effect of Intestinal Remote Ischemic Conditioning in a Rat Model of Total Hepatic Ischemia. J Clin Med 2019;8:E1546. [PMID: 31561505 DOI: 10.3390/jcm8101546] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
219 Pörner D, Von Vietinghoff S, Nattermann J, Strassburg CP, Lutz P. Advances in the pharmacological management of bacterial peritonitis. Expert Opin Pharmacother 2021;22:1567-78. [PMID: 33878993 DOI: 10.1080/14656566.2021.1915288] [Reference Citation Analysis]
220 Kooij KW, Wit FW, van Zoest RA, Schouten J, Kootstra NA, van Vugt M, Prins M, Reiss P, van der Valk M; AGEhIV Cohort Study Group. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. AIDS. 2016;30:1771-1780. [PMID: 27088320 DOI: 10.1097/qad.0000000000001119] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
221 Lutz P, M Haimid M, Pohlmann A, Lehmann J, Jansen C, Schierwagen R, Klein S, Strassburg CP, Spengler U, Trebicka J. MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis. Sci Rep 2017;7:40556. [PMID: 28074870 DOI: 10.1038/srep40556] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
222 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
223 Zou Y, Li S, Xu B, Guo H, Zhang S, Cai Y. Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia. Inflammation 2020;43:251-63. [PMID: 31776890 DOI: 10.1007/s10753-019-01114-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
224 Di Profio B, Villar CC, Saraiva L, Ortega KL, Pannuti CM. Is periodontitis a risk factor for infections in cirrhotic patients? Med Hypotheses 2017;106:19-22. [PMID: 28818265 DOI: 10.1016/j.mehy.2017.06.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
225 Clària J, Arroyo V, Moreau R. The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. J Immunol 2016;197:3755-61. [PMID: 27815438 DOI: 10.4049/jimmunol.1600818] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 14.0] [Reference Citation Analysis]
226 Piano S, Brocca A, Mareso S, Angeli P. Infections complicating cirrhosis. Liver Int. 2018;38 Suppl 1:126-133. [PMID: 29427501 DOI: 10.1111/liv.13645] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 28.0] [Reference Citation Analysis]
227 Wiest R. The Gut Microbiome and Cirrhosis: Basic Aspects. In: de Franchis R, editor. Portal Hypertension VI. Cham: Springer International Publishing; 2016. pp. 139-68. [DOI: 10.1007/978-3-319-23018-4_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
228 Rainer F, Horvath A, Sandahl TD, Leber B, Schmerboeck B, Blesl A, Groselj-Strele A, Stauber RE, Fickert P, Stiegler P, Møller HJ, Grønbaek H, Stadlbauer V. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. Aliment Pharmacol Ther 2018;47:657-64. [PMID: 29266346 DOI: 10.1111/apt.14474] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
229 Gao JH, Wen SL, Tong H, Wang CH, Yang WJ, Tang SH, Yan ZP, Tai Y, Ye C, Liu R. Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats. Am J Physiol Gastrointest Liver Physiol. 2016;310:G962-G972. [PMID: 27056726 DOI: 10.1152/ajpgi.00428.2015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
230 Garcia-Broncano P, Medrano LM, Berenguer J, Brochado-Kith O, González-García J, Jiménez-Sousa MÁ, Quereda C, Sanz J, Téllez MJ, Díaz L, JIménez JL, Resino S; GESIDA 3603b Study Group. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study. J Infect 2020;80:99-110. [PMID: 31585189 DOI: 10.1016/j.jinf.2019.09.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
231 Klag T, Thomas M, Ehmann D, Courth L, Mailänder-Sanchez D, Weiss TS, Dayoub R, Abshagen K, Vollmar B, Thasler WE, Stange EF, Berg CP, Malek NP, Zanger UM, Wehkamp J. β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor. Front Immunol 2018;9:1735. [PMID: 30100908 DOI: 10.3389/fimmu.2018.01735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
232 Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients: . Current Opinion in HIV and AIDS 2015;10:309-15. [DOI: 10.1097/coh.0000000000000175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
233 Medrano LM, Garcia-Broncano P, Berenguer J, González-García J, Jiménez-Sousa MÁ, Guardiola JM, Crespo M, Quereda C, Sanz J, Canorea I, Carrero A, Hontañón V, Muñoz-Fernández MÁ, Resino S; GESIDA 3603b Study Group. Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. AIDS 2018;32:1095-105. [PMID: 29438197 DOI: 10.1097/QAD.0000000000001787] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
234 Moharem HA, Fetouh FA, Darwish HM, Ghaith D, Elayashy M, Hussein A, Elsayed R, Khalil MM, Abdelaal A, ElMeteini M, Mukhtar A. Effects of bacterial translocation on hemodynamic and coagulation parameters during living-donor liver transplant. BMC Anesthesiol 2018;18:46. [PMID: 29699477 DOI: 10.1186/s12871-018-0507-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
235 Cheng C, Tan J, Qian W, Zhang L, Hou X. Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction. Life Sci. 2018;209:157-166. [PMID: 30096384 DOI: 10.1016/j.lfs.2018.08.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
236 Fedosina EA, Byeverov AO, Bogomolov PO, Staroverova NP. [Some practical issues in the management of patients with decompensated liver cirrhosis]. Ter Arkh 2019;91:148-54. [PMID: 32598767 DOI: 10.26442/00403660.2019.08.000391] [Reference Citation Analysis]
237 Boaretti M, Castellani F, Merli M, Lucidi C, Lleo MM. Presence of multiple bacterial markers in clinical samples might be useful for presumptive diagnosis of infection in cirrhotic patients with culture-negative reports. Eur J Clin Microbiol Infect Dis 2016;35:433-41. [DOI: 10.1007/s10096-015-2556-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
238 Solé C, Guilly S, Da Silva K, Llopis M, Le-Chatelier E, Huelin P, Carol M, Moreira R, Fabrellas N, De Prada G, Napoleone L, Graupera I, Pose E, Juanola A, Borruel N, Berland M, Toapanta D, Casellas F, Guarner F, Doré J, Solà E, Ehrlich SD, Ginès P. Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. Gastroenterology 2021;160:206-218.e13. [PMID: 32941879 DOI: 10.1053/j.gastro.2020.08.054] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
239 Zhao T, Zhu Y, Yao L, Liu L, Li N. IGF-1 alleviates CCL4-induced hepatic cirrhosis and dysfunction of intestinal barrier through inhibition TLR4/NF-κB signaling mediated by down-regulation HMGB1. Ann Hepatol 2021;:100560. [PMID: 34653689 DOI: 10.1016/j.aohep.2021.100560] [Reference Citation Analysis]
240 Juanola O, Piñero P, Gómez-Hurtado I, Caparrós E, García-Villalba R, Marín A, Zapater P, Tarín F, González-Navajas JM, Tomás-Barberán FA, Francés R. Regulatory T Cells Restrict Permeability to Bacterial Antigen Translocation and Preserve Short-Chain Fatty Acids in Experimental Cirrhosis. Hepatol Commun 2018;2:1610-23. [PMID: 30556045 DOI: 10.1002/hep4.1268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
241 Wiest R, Lawson M, Geuking M. Reply to: "bacterial translocation in liver cirrhosis: site and role in fibrogenesis". J Hepatol 2014;61:710-1. [PMID: 24929092 DOI: 10.1016/j.jhep.2014.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
242 Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. Journal of Hepatology 2015;63:1272-84. [DOI: 10.1016/j.jhep.2015.07.004] [Cited by in Crossref: 272] [Cited by in F6Publishing: 237] [Article Influence: 45.3] [Reference Citation Analysis]
243 Han WM, Ueaphongsukkit T, Chattranukulchai P, Siwamogsatham S, Chaiteerakij R, Sophonphan J, Gatechompol S, Ubolyam S, Phonphithak S, Ruxrungtham K, Tangkijvanich P, Avihingsanon Y, Kerr SJ, Avihingsanon A. Incident Liver Cirrhosis, Associated Factors, and Cardiovascular Disease Risks Among People Living With HIV: A Longitudinal Study. J Acquir Immune Defic Syndr 2021;86:463-72. [PMID: 33273213 DOI: 10.1097/QAI.0000000000002585] [Reference Citation Analysis]
244 Zaccherini G, Weiss E, Moreau R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. JHEP Rep 2021;3:100176. [PMID: 33205036 DOI: 10.1016/j.jhepr.2020.100176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
245 Lu YX, Chang YZ, Liang P, Yang CQ. Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir. Infect Dis Ther 2021;10:1519-30. [PMID: 34132991 DOI: 10.1007/s40121-021-00463-1] [Reference Citation Analysis]
246 Fung TC, Artis D, Sonnenberg GF. Anatomical localization of commensal bacteria in immune cell homeostasis and disease. Immunol Rev 2014;260:35-49. [PMID: 24942680 DOI: 10.1111/imr.12186] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
247 Mohandas S, Vairappan B. Role of pregnane X-receptor in regulating bacterial translocation in chronic liver diseases. World J Hepatol 2017; 9(32): 1210-1226 [PMID: 29184608 DOI: 10.4254/wjh.v9.i32.1210] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
248 Usui S, Ebinuma H, Chu PS, Nakamoto N, Yamagishi Y, Saito H, Kanai T. Detection of bacterial DNA by in situ hybridization in patients with decompensated liver cirrhosis. BMC Gastroenterol. 2017;17:106. [PMID: 29041907 DOI: 10.1186/s12876-017-0664-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
249 Meyer F, Bannert K, Wiese M, Esau S, Sautter LF, Ehlers L, Aghdassi AA, Metges CC, Garbe LA, Jaster R, Lerch MM, Lamprecht G, Valentini L. Molecular Mechanism Contributing to Malnutrition and Sarcopenia in Patients with Liver Cirrhosis. Int J Mol Sci 2020;21:E5357. [PMID: 32731496 DOI: 10.3390/ijms21155357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
250 Casulleras M, Zhang IW, López-Vicario C, Clària J. Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. Cells 2020;9:E2632. [PMID: 33302342 DOI: 10.3390/cells9122632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
251 Bhat M, Arendt BM, Bhat V, Renner EL, Humar A, Allard JP. Implication of the intestinal microbiome in complications of cirrhosis. World J Hepatol 2016; 8(27): 1128-1136 [PMID: 27721918 DOI: 10.4254/wjh.v8.i27.1128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
252 Hussain M, Umair Ijaz M, Ahmad MI, Khan IA, Bukhary SUF, Khan W, Hussain S, Hashmi MS, Li C. Gut inflammation exacerbates hepatic injury in C57BL/6J mice via gut-vascular barrier dysfunction with high-fat-incorporated meat protein diets. Food Funct 2020;11:9168-76. [PMID: 33026380 DOI: 10.1039/d0fo02153a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Tufoni M, Baldassarre M, Zaccherini G, Antognoli A, Caraceni P. Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. Curr Hepatol Rep 2020;:1-12. [PMID: 32837825 DOI: 10.1007/s11901-020-00521-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
254 Ruiz-del-Árbol L, Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol 2015; 21(41): 11502-11521 [PMID: 26556983 DOI: 10.3748/wjg.v21.i41.11502] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 55] [Article Influence: 13.0] [Reference Citation Analysis]
255 Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014;61:396-407. [PMID: 24751830 DOI: 10.1016/j.jhep.2014.04.012] [Cited by in Crossref: 193] [Cited by in F6Publishing: 182] [Article Influence: 27.6] [Reference Citation Analysis]
256 Putignani L, Del Chierico F, Vernocchi P, Cicala M, Cucchiara S, Dallapiccola B; Dysbiotrack Study Group. Gut Microbiota Dysbiosis as Risk and Premorbid Factors of IBD and IBS Along the Childhood-Adulthood Transition. Inflamm Bowel Dis 2016;22:487-504. [PMID: 26588090 DOI: 10.1097/MIB.0000000000000602] [Cited by in Crossref: 54] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
257 Mücke MM, Mücke VT, Graf C, Schwarzkopf KM, Ferstl PG, Fernandez J, Zeuzem S, Trebicka J, Lange CM, Herrmann E. Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol 2020;11:e00223. [PMID: 32955202 DOI: 10.14309/ctg.0000000000000223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
258 Singanayagam A, Triantafyllou E. Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting. Front Immunol 2021;12:661182. [PMID: 33868313 DOI: 10.3389/fimmu.2021.661182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
259 Sorribas M, Jakob MO, Yilmaz B, Li H, Stutz D, Noser Y, de Gottardi A, Moghadamrad S, Hassan M, Albillos A, Francés R, Juanola O, Spadoni I, Rescigno M, Wiest R. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J Hepatol 2019;71:1126-40. [PMID: 31295531 DOI: 10.1016/j.jhep.2019.06.017] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 23.0] [Reference Citation Analysis]
260 Khamri W, Gudd C, Liu T, Nathwani R, Krasniqi M, Azam S, Barbera T, Trovato FM, Possamai L, Triantafyllou E, Seoane RC, Lebosse F, Singanayagam A, Kumar N, Bernsmeier C, Mukherjee S, McPhail M, Weston CJ, Antoniades CG, Thursz MR. Suppressor CD4+ T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis. Gut 2021:gutjnl-2021-324071. [PMID: 34344786 DOI: 10.1136/gutjnl-2021-324071] [Reference Citation Analysis]
261 Noor MT, Manoria P. Immune Dysfunction in Cirrhosis. J Clin Transl Hepatol. 2017;5:50-58. [PMID: 28507927 DOI: 10.14218/jcth.2016.00056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
262 Shigefuku R, Iwasa M, Eguchi A, Tamai Y, Yoshikawa K, Sugimoto R, Takei Y. Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease. J Gastroenterol Hepatol 2021;36:1006-14. [PMID: 32790956 DOI: 10.1111/jgh.15215] [Reference Citation Analysis]
263 Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Probiotics in hepatology: An update. World J Hepatol 2021; 13(9): 1154-1166 [PMID: 34630882 DOI: 10.4254/wjh.v13.i9.1154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Lee PC, Hsieh YC, Huo TI, Yang UC, Lin CH, Li CP, Huang YH, Hou MC, Lin HC, Lee KC. Active Vitamin D3 Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats. Mol Nutr Food Res 2021;65:e2000937. [PMID: 33258263 DOI: 10.1002/mnfr.202000937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
265 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
266 Vijayaraghavan R, Maiwall R, Arora V, Choudhary A, Benjamin J, Aggarwal P, Jamwal KD, Kumar G, Joshi YK, Sarin SK. Reversal of Feed Intolerance by Prokinetics Improves Survival in Critically Ill Cirrhosis Patients. Dig Dis Sci 2021. [PMID: 34392492 DOI: 10.1007/s10620-021-07185-x] [Reference Citation Analysis]
267 Ferrarese A, Zanetto A, Becchetti C, Sciarrone SS, Shalaby S, Germani G, Gambato M, Russo FP, Burra P, Senzolo M. Management of bacterial infection in the liver transplant candidate. World J Hepatol 2018; 10(2): 222-230 [PMID: 29527258 DOI: 10.4254/wjh.v10.i2.222] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
268 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
269 Lutz P, Krämer B, Kaczmarek DJ, Hübner MP, Langhans B, Appenrodt B, Lammert F, Nattermann J, Hoerauf A, Strassburg CP, Spengler U, Nischalke HD. A variant in the nuclear dot protein 52kDa gene increases the risk for spontaneous bacterial peritonitis in patients with alcoholic liver cirrhosis. Dig Liver Dis 2016;48:62-8. [PMID: 26493630 DOI: 10.1016/j.dld.2015.09.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
270 Han P, Sun D, Yang J. Interaction between periodontitis and liver diseases. Biomed Rep 2016;5:267-76. [PMID: 27588170 DOI: 10.3892/br.2016.718] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
271 Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2018;15:753-64. [DOI: 10.1038/s41575-018-0045-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
272 Fujiya Y, Hayakawa K, Gu Y, Yamamoto K, Mawatari M, Kutsuna S, Takeshita N, Kato Y, Kanagawa S, Ohmagari N. Age-related differences in clinical characteristics of invasive group G streptococcal infection: Comparison with group A and group B streptococcal infections. PLoS One 2019;14:e0211786. [PMID: 30845149 DOI: 10.1371/journal.pone.0211786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
273 Abootalebi A, Khazaei S, Minakari M, Nasr-Isfahani M, Esmailian M, Heydari F. Comparing the Effects of Hydroxyethyl Starch and Albumin in Cirrhotic Patients with Tense Ascites; a Randomized Clinical Trial. Adv J Emerg Med 2017;1:e7. [PMID: 31172059 DOI: 10.22114/AJEM.v1i1.17] [Reference Citation Analysis]
274 Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol. 2016;65:809-824. [PMID: 27238754 DOI: 10.1016/j.jhep.2016.05.025] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 14.2] [Reference Citation Analysis]
275 Marongiu L, Landry JJM, Rausch T, Abba ML, Delecluse S, Delecluse HJ, Allgayer H. Metagenomic analysis of primary colorectal carcinomas and their metastases identifies potential microbial risk factors. Mol Oncol 2021. [PMID: 34328665 DOI: 10.1002/1878-0261.13070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
276 Zapater P, González-Navajas JM, Such J, Francés R. Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis. World J Gastroenterol 2015; 21(41): 11493-11501 [PMID: 26556982 DOI: 10.3748/wjg.v21.i41.11493] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
277 Moreau R, Elkrief L, Bureau C, Perarnau J, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-hourmand I, Robic MA, d'Alteroche L, Di Martino V, Ripault M, Pauwels A, Grangé J, Carbonell N, Bronowicki J, Payancé A, Rautou P, Valla D, Gault N, Lebrec D. Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology 2018;155:1816-1827.e9. [DOI: 10.1053/j.gastro.2018.08.026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 17.7] [Reference Citation Analysis]
278 Fukui H, Wiest R. Changes of Intestinal Functions in Liver Cirrhosis. Inflamm Intest Dis. 2016;1:24-40. [PMID: 29922655 DOI: 10.1159/000444436] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
279 Vieira SMG, Schwengber FP, Melere M, Ceza MR, Souza M, Kieling CO. The first episode of spontaneous bacterial peritonitis is a threat event in children with end-stage liver disease. Eur J Gastroenterol Hepatol 2018;30:323-7. [PMID: 29303884 DOI: 10.1097/MEG.0000000000001046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
280 Niu M, Luo Z, Gong S, Win S, Kaplowitz N, Jiang Y, Chen P. Intestinal Epithelial Chemokine (C-C Motif) Ligand 7 Overexpression Enhances Acetaminophen-Induced Hepatotoxicity in Mice. Am J Pathol 2020;190:57-67. [PMID: 31610172 DOI: 10.1016/j.ajpath.2019.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
281 Okada N, Sanada Y, Urahashi T, Ihara Y, Yamada N, Hirata Y, Katano T, Otomo S, Ushijima K, Mizuta K. Endotoxin Metabolism Reflects Hepatic Functional Reserve in End-Stage Liver Disease. Transplantation Proceedings 2018;50:1360-4. [DOI: 10.1016/j.transproceed.2018.01.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
282 Juanola O, Gómez-Hurtado I, Zapater P, Moratalla A, Caparrós E, Piñero P, González-Navajas JM, Giménez P, Such J, Francés R. Selective intestinal decontamination with norfloxacin enhances a regulatory T cell-mediated inflammatory control mechanism in cirrhosis. Liver Int 2016;36:1811-20. [PMID: 27214392 DOI: 10.1111/liv.13172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
283 Gracia-sancho J, Hernández-gea V, Garcia-pagán JC. Obeticholic acid: A new light in the shadows treating portal hypertension?: GRACIA-SANCHO, HERNÁNDEZ-GEA, AND GARCÍA-PAGÁN. Hepatology 2014;59:2072-3. [DOI: 10.1002/hep.27027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
284 Hof H. Rhodotorula spp. in the gut - foe or friend? GMS Infect Dis 2019;7:Doc02. [PMID: 31538040 DOI: 10.3205/id000042] [Reference Citation Analysis]
285 Ko ER, Philipson CW, Burke TW, Cer RZ, Bishop-Lilly KA, Voegtly LJ, Tsalik EL, Woods CW, Clark DV, Schully KL. Direct-from-blood RNA sequencing identifies the cause of post-bronchoscopy fever. BMC Infect Dis 2019;19:905. [PMID: 31660864 DOI: 10.1186/s12879-019-4462-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
286 Shi D, Lv L, Fang D, Wu W, Hu C, Xu L, Chen Y, Guo J, Hu X, Li A, Guo F, Ye J, Li Y, Andayani D, Li L. Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 prevents CCl4-induced liver cirrhosis by protecting the intestinal barrier in rats. Sci Rep 2017;7:6927. [PMID: 28761060 DOI: 10.1038/s41598-017-07091-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
287 Oey RC, de Man RA, Erler NS, Verbon A, van Buuren HR. Microbiology and antibiotic susceptibility patterns in spontaneous bacterial peritonitis: A study of two Dutch cohorts at a 10-year interval. United European Gastroenterol J 2018;6:614-21. [PMID: 29881617 DOI: 10.1177/2050640617744456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
288 Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759-791. [PMID: 27682116 DOI: 10.3390/microorganisms3040759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
289 Ponziani FR, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol. 2018;12:641-656. [PMID: 29806487 DOI: 10.1080/17474124.2018.1481747] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 14.0] [Reference Citation Analysis]
290 Janka T, Tornai T, Borbély B, Tornai D, Altorjay I, Papp M, Vitális Z. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis. Eur J Gastroenterol Hepatol 2020;32:257-64. [PMID: 31464790 DOI: 10.1097/MEG.0000000000001499] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
291 Assimakopoulos SF, Triantos C, Thomopoulos K, Fligou F, Maroulis I, Marangos M, Gogos CA. Gut-origin sepsis in the critically ill patient: pathophysiology and treatment. Infection. 2018;46:751-760. [PMID: 30003491 DOI: 10.1007/s15010-018-1178-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 15.0] [Reference Citation Analysis]
292 Tan-Garcia A, Lai F, Sheng Yeong JP, Irac SE, Ng PY, Msallam R, Tatt Lim JC, Wai LE, Tham CYL, Choo SP, Lim T, Young DY, D'Ambrosio R, Degasperi E, Perbellini R, Newell E, Le Bert N, Ginhoux F, Bertoletti A, Chen Q, Dutertre CA. Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy. JHEP Rep 2020;2:100062. [PMID: 32039403 DOI: 10.1016/j.jhepr.2019.11.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
293 Liaskou E, Hirschfield GM. Cirrhosis-associated immune dysfunction: Novel insights in impaired adaptive immunity. EBioMedicine 2019;50:3-4. [PMID: 31727600 DOI: 10.1016/j.ebiom.2019.10.056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
294 Bruns T, Reuken PA, Stengel S, Gerber L, Appenrodt B, Schade JH, Lammert F, Zeuzem S, Stallmach A. The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection. Liver Int 2016;36:1133-42. [PMID: 26901072 DOI: 10.1111/liv.13095] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
295 Turco L, Garcia-Tsao G, Magnani I, Bianchini M, Costetti M, Caporali C, Colopi S, Simonini E, De Maria N, Banchelli F, Rossi R, Villa E, Schepis F. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. J Hepatol. 2018;68:949-958. [PMID: 29331339 DOI: 10.1016/j.jhep.2017.12.027] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 20.0] [Reference Citation Analysis]
296 Chung PH, Wu YY, Chen PH, Fung CP, Hsu CM, Chen LW. Lactobacillus salivarius reverse diabetes-induced intestinal defense impairment in mice through non-defensin protein. J Nutr Biochem 2016;35:48-57. [PMID: 27376728 DOI: 10.1016/j.jnutbio.2016.05.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
297 Ponziani FR, Valenza V, Nure E, Bianco G, Marrone G, Grieco A, Pompili M, Gasbarrini A, Agnes S, Sganga G. Effect of liver transplantation on intestinal permeability and correlation with infection episodes. PLoS One 2020;15:e0235359. [PMID: 32589654 DOI: 10.1371/journal.pone.0235359] [Reference Citation Analysis]
298 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
299 Tang R, Wei Y, Li Y, Chen W, Chen H, Wang Q, Yang F, Miao Q, Xiao X, Zhang H, Lian M, Jiang X, Zhang J, Cao Q, Fan Z, Wu M, Qiu D, Fang JY, Ansari A, Gershwin ME, Ma X. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018;67:534-41. [PMID: 28213609 DOI: 10.1136/gutjnl-2016-313332] [Cited by in Crossref: 148] [Cited by in F6Publishing: 144] [Article Influence: 37.0] [Reference Citation Analysis]
300 Arai N, Mine Y, Kagami H, Inaba M. Rush progression and fatal result of septic shock related to central line catheter infection in cirrhosis patient with brain stroke. BMC Neurol 2018;18:158. [PMID: 30268118 DOI: 10.1186/s12883-018-1166-5] [Reference Citation Analysis]
301 Úbeda M, Lario M, Muñoz L, Borrero MJ, Rodríguez-Serrano M, Sánchez-Díaz AM, Del Campo R, Lledó L, Pastor Ó, García-Bermejo L, Díaz D, Álvarez-Mon M, Albillos A. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol 2016;64:1049-57. [PMID: 26723896 DOI: 10.1016/j.jhep.2015.12.010] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 13.3] [Reference Citation Analysis]
302 Marconi C, Bellan M, Giarda P, Minisini R, Favretto S, Burlone ME, Franzosi L, Pirisi M. Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C. Ann Gastroenterol 2017;30:675-81. [PMID: 29118563 DOI: 10.20524/aog.2017.0190] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
303 Mücke MM, Rüschenbaum S, Mayer A, Mücke VT, Schwarzkopf KM, Zeuzem S, Kehrmann J, Scholtysik R, Lange CM. Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study. Gut Pathog 2020;12:51. [PMID: 33133240 DOI: 10.1186/s13099-020-00389-y] [Reference Citation Analysis]
304 Yan J, Wang D, Li K, Chen Q, Lai W, Tian L, Lin B, Tan Y, Liu X, Xi Z. Toxic effects of the food additives titanium dioxide and silica on the murine intestinal tract: Mechanisms related to intestinal barrier dysfunction involved by gut microbiota. Environ Toxicol Pharmacol 2020;80:103485. [PMID: 32891757 DOI: 10.1016/j.etap.2020.103485] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
305 Li TH, Liu CW, Huang CC, Tsai YL, Huang SF, Yang YY, Tsai CY, Hou MC, Lin HC. Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study. J Clin Med 2021;10:2244. [PMID: 34064207 DOI: 10.3390/jcm10112244] [Reference Citation Analysis]
306 Khalesi S, Johnson DW, Campbell K, Williams S, Fenning A, Saluja S, Irwin C. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. Eur J Nutr 2018;57:2037-53. [PMID: 29119235 DOI: 10.1007/s00394-017-1568-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
307 Traykova D, Schneider B, Chojkier M, Buck M. Blood Microbiome Quantity and the Hyperdynamic Circulation in Decompensated Cirrhotic Patients. PLoS One 2017;12:e0169310. [PMID: 28146577 DOI: 10.1371/journal.pone.0169310] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
308 Shen TD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver: Microbiota and the Liver. Liver Transpl 2018;24:539-50. [DOI: 10.1002/lt.25008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
309 Abdel-razik A, Eldars W, Elhelaly R, Eldeeb AA, Abdelsalam M, El-wakeel N, Aboulmagd A. Homocysteine: a new diagnostic marker in spontaneous bacterial peritonitis. European Journal of Gastroenterology & Hepatology 2018;30:779-85. [DOI: 10.1097/meg.0000000000001109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 4.3] [Reference Citation Analysis]
310 Assimakopoulos SF, Triantos C, Maroulis I, Gogos C. The Role of the Gut Barrier Function in Health and Disease. Gastroenterology Res 2018;11:261-3. [PMID: 30116424 DOI: 10.14740/gr1053w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
311 Ra G, Tsien C, Renner EL, Wong FS. The Negative Prognostic Impact of a First Ever Episode of Spontaneous Bacterial Peritonitis in Cirrhosis and Ascites. Journal of Clinical Gastroenterology 2015;49:858-65. [DOI: 10.1097/mcg.0000000000000311] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
312 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-460. [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024] [Cited by in Crossref: 660] [Cited by in F6Publishing: 527] [Article Influence: 220.0] [Reference Citation Analysis]
313 Cui Y, Qi S, Zhang W, Mao J, Tang R, Wang C, Liu J, Luo XM, Wang H. Lactobacillus reuteri ZJ617 Culture Supernatant Attenuates Acute Liver Injury Induced in Mice by Lipopolysaccharide. The Journal of Nutrition 2019;149:2046-55. [DOI: 10.1093/jn/nxz088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
314 Pouriki S, Vrioni G, Sambatakou H, Alexopoulou A, Vasilieva L, Mani I, Tsakris A, Dourakis SP. Intestinal colonization with resistant bacteria: a prognostic marker of mortality in decompensated cirrhosis. Eur J Clin Microbiol Infect Dis 2018;37:127-34. [DOI: 10.1007/s10096-017-3110-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
315 Szeto CC, McIntyre CW, Li PK. Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD. J Am Soc Nephrol 2018;29:1601-8. [PMID: 29666156 DOI: 10.1681/ASN.2018010068] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
316 Zhang T, Sun K, Wang Y, Huang L, Lang R, Jiang W. Disruption of the gut-liver axis in the pathogenesis of acute-on-chronic liver failure. Eur J Gastroenterol Hepatol 2018;30:130-5. [PMID: 29200007 DOI: 10.1097/MEG.0000000000001026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
317 Zuccaro V, Columpsi P, Sacchi P, Lucà MG, Fagiuoli S, Bruno R. Antibiotic stewardship and empirical antibiotic treatment: How can they get along? Digestive and Liver Disease 2017;49:579-84. [DOI: 10.1016/j.dld.2017.01.157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
318 Lechner S, Yee M, Limketkai BN, Pham EA. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Dig Dis Sci 2020;65:897-905. [PMID: 32020359 DOI: 10.1007/s10620-020-06100-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
319 Li Q, Wang C, Tang C, Zhao X, He Q, Li J. Identification and Characterization of Blood and Neutrophil-Associated Microbiomes in Patients with Severe Acute Pancreatitis Using Next-Generation Sequencing. Front Cell Infect Microbiol 2018;8:5. [PMID: 29423379 DOI: 10.3389/fcimb.2018.00005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
320 Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe 2016;19:227-39. [PMID: 26867181 DOI: 10.1016/j.chom.2016.01.003] [Cited by in Crossref: 169] [Cited by in F6Publishing: 161] [Article Influence: 33.8] [Reference Citation Analysis]
321 Strnad P, Tacke F, Koch A, Trautwein C. Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2017;14:55-66. [PMID: 27924081 DOI: 10.1038/nrgastro.2016.168] [Cited by in Crossref: 168] [Cited by in F6Publishing: 156] [Article Influence: 33.6] [Reference Citation Analysis]
322 Márquez M, Fernández Gutiérrez del Álamo C, Girón-González JA. Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity. World J Gastroenterol 2016; 22(4): 1433-1448 [PMID: 26819512 DOI: 10.3748/wjg.v22.i4.1433] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
323 Gao F, Cai MX, Lin MT, Zhang LZ, Ruan QZ, Gao F. Model for end-stage liver disease and pneumonia: An improved scoring model for critically ill cirrhotic patients with pneumonia. Turk J Gastroenterol 2019;30:532-40. [PMID: 31144659 DOI: 10.5152/tjg.2019.18421] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
324 Vermathen P, Diserens G, Kröll D, Nett P, Stirnimann G, Wiest R. Determination of bile acids from human gallbladder by 1 H-MRS-Protocol optimization and estimation of reproducibility. NMR Biomed 2021;34:e4432. [PMID: 33118656 DOI: 10.1002/nbm.4432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
325 Fan Y, Li Y, Chu Y, Liu J, Cui L, Zhang D. Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis. Front Immunol 2021;12:608498. [PMID: 33708204 DOI: 10.3389/fimmu.2021.608498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Allaire M, Cadranel JF, Nguyen TTN, Garioud A, Zougmore H, Heng R, Perignon C, Ollivier-Hourmand I, Dao T. Management of infections in patients with cirrhosis in the context of increasing therapeutic resistance: A systematic review. Clin Res Hepatol Gastroenterol 2020;44:264-74. [PMID: 31706985 DOI: 10.1016/j.clinre.2019.10.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
327 Lutz P, Nischalke HD, Krämer B, Goeser F, Kaczmarek DJ, Schlabe S, Parcina M, Nattermann J, Hoerauf A, Strassburg CP, Spengler U. Antibiotic resistance in healthcare-related and nosocomial spontaneous bacterial peritonitis. Eur J Clin Invest 2017;47:44-52. [PMID: 27861767 DOI: 10.1111/eci.12701] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
328 Cheng R, Guo J, Zhang Y, Cheng G, Qian W, Wan C, Li M, Marotta F, Shen X, He F. Impacts of ceftriaxone exposure during pregnancy on maternal gut and placental microbiota and its influence on maternal and offspring immunity in mice. Exp Anim 2021;70:203-17. [PMID: 33268669 DOI: 10.1538/expanim.20-0114] [Reference Citation Analysis]
329 Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert Rev Gastroenterol Hepatol. 2015;9:1069-1076. [PMID: 26088524 DOI: 10.1586/17474124.2015.1057122] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
330 Meissner EG. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis 2018;67:878-80. [PMID: 29718134 DOI: 10.1093/cid/ciy208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
331 Wan SZ, Liu C, Huang CK, Luo FY, Zhu X. Ursolic Acid Improves Intestinal Damage and Bacterial Dysbiosis in Liver Fibrosis Mice. Front Pharmacol 2019;10:1321. [PMID: 31736766 DOI: 10.3389/fphar.2019.01321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
332 Gómez-Hurtado I, Such J, Francés R. Microbiome and bacterial translocation in cirrhosis. Gastroenterol Hepatol 2016;39:687-96. [PMID: 26775042 DOI: 10.1016/j.gastrohep.2015.10.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
333 Moghadamrad S, Hassan M, McCoy KD, Kirundi J, Kellmann P, De Gottardi A. Attenuated fibrosis in specific pathogen-free microbiota in experimental cholestasis- and toxin-induced liver injury. FASEB J 2019;33:12464-76. [PMID: 31431085 DOI: 10.1096/fj.201901113R] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
334 Wen JB, Zhu FQ, Chen WG, Jiang LP, Chen J, Hu ZP, Huang YJ, Zhou ZW, Wang GL, Lin H. Oxymatrine improves intestinal epithelial barrier function involving NF-κB-mediated signaling pathway in CCl4-induced cirrhotic rats. PLoS One. 2014;9:e106082. [PMID: 25171482 DOI: 10.1371/journal.pone.0106082] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
335 Khemichian S, Francoz C, Durand F, Karvellas CJ, Nadim MK. Hepatorenal Syndrome. Crit Care Clin 2021;37:321-34. [PMID: 33752858 DOI: 10.1016/j.ccc.2020.11.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
336 Paine CH, Biggins SW, Pichler RH. Albumin in Cirrhosis: More Than a Colloid. Curr Treat Options Gastro 2019;17:231-43. [DOI: 10.1007/s11938-019-00227-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
337 Martínez-Esparza M, Tristán-Manzano M, Ruiz-Alcaraz AJ, García-Peñarrubia P. Inflammatory status in human hepatic cirrhosis. World J Gastroenterol 2015; 21(41): 11522-11541 [PMID: 26556984 DOI: 10.3748/wjg.v21.i41.11522] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
338 Cao Y, Shi H, Sun Z, Wu J, Xia Y, Wang Y, Wu Y, Li X, Chen W, Wang A, Lu Y. Protective Effects of Magnesium Glycyrrhizinate on Methotrexate-Induced Hepatotoxicity and Intestinal Toxicity May Be by Reducing COX-2. Front Pharmacol 2019;10:119. [PMID: 30971913 DOI: 10.3389/fphar.2019.00119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
339 Malev AL, Zakharova AN, Kaliberdenko VB, Fominykh TA, Kulanthaivel S, Balasundaram K. Structural and Morphological Changes in the Liver Due to Intestinal Endotoxins. Rev Recent Clin Trials 2020;15:205-13. [PMID: 32552644 DOI: 10.2174/1574887115666200617143422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
340 Yuan Y, Han Q, Li S, Tian Z, Zhang J. Wnt2b attenuates HSCs activation and liver fibrosis through negative regulating TLR4 signaling. Sci Rep 2017;7:3952. [PMID: 28638086 DOI: 10.1038/s41598-017-04374-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
341 Liu CP, Chiang TT, Liu YM, Kuo SC, Yang YS, Lee YT, Chen TL, Shih SC; ACTION Study Group. A multicenter study on clinical characteristics of Acinetobacter bacteremia in patients with liver cirrhosis. J Microbiol Immunol Infect 2019;52:956-65. [PMID: 29731384 DOI: 10.1016/j.jmii.2018.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
342 Alukal JJ, Thuluvath PJ. Gastrointestinal Failure in Critically Ill Patients With Cirrhosis. Am J Gastroenterol 2019;114:1231-7. [PMID: 31185004 DOI: 10.14309/ajg.0000000000000226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
343 Riva A, Gray EH, Azarian S, Zamalloa A, McPhail MJW, Vincent RP, Williams R, Chokshi S, Patel VC, Edwards LA. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. JHEP Rep 2020;2:100151. [PMID: 32838247 DOI: 10.1016/j.jhepr.2020.100151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
344 Elefsiniotis I, Tsakiris SA, Barla G, Tasovasili A, Vrachatis D, Mavrogiannis C. Presepsin levels in cirrhotic patients with bacterial infections and/or portal hypertension-related bleeding, presenting with or without acute kidney injury. Ann Gastroenterol 2018;31:604-12. [PMID: 30174398 DOI: 10.20524/aog.2018.0292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
345 武超, 刘平, 孙明瑜, 边艳琴. 巨噬细胞亚群与肝病研究进展. 世界华人消化杂志 2016; 24(33): 4491-4497 [DOI: 10.11569/wcjd.v24.i33.4491] [Reference Citation Analysis]
346 Patten DA, Kamarajah SK, Rose JM, Tickle J, Shepherd EL, Adams DH, Weston CJ, Shetty S. SCARF-1 promotes adhesion of CD4+ T cells to human hepatic sinusoidal endothelium under conditions of shear stress. Sci Rep 2017;7:17600. [PMID: 29242513 DOI: 10.1038/s41598-017-17928-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
347 Schumann M, Siegmund B, Schulzke JD, Fromm M. Celiac Disease: Role of the Epithelial Barrier. Cell Mol Gastroenterol Hepatol. 2017;3:150-162. [PMID: 28275682 DOI: 10.1016/j.jcmgh.2016.12.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 17.0] [Reference Citation Analysis]
348 Rodríguez-Laiz GP, Zapater P, Melgar P, Alcázar C, Franco M, Giménez P, Pascual S, Bellot P, Palazón JM, Rodríguez M, Carnicer F, Más-Serrano P, González-Navajas JM, Gómez L, Such J, Lluís F, Francés R; Liver Transplantation Group. Bacterial DNA translocation contributes to systemic inflammation and to minor changes in the clinical outcome of liver transplantation. Sci Rep 2019;9:835. [PMID: 30696924 DOI: 10.1038/s41598-018-36904-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
349 Meng J, Wang Q, Liu K, Yang S, Fan X, Liu B, He C, Wu X. Systemic and Splanchnic Lipopolysaccharide and Endothelin-1 Plasma Levels in Liver Cirrhosis before and after Transjugular Intrahepatic Portosystemic Shunt. Gastroenterol Res Pract 2016;2016:8341030. [PMID: 26941788 DOI: 10.1155/2016/8341030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
350 Davies T, Wythe S, O'Beirne J, Martin D, Gilbert-Kawai E. Review article: the role of the microcirculation in liver cirrhosis. Aliment Pharmacol Ther 2017;46:825-35. [PMID: 29023881 DOI: 10.1111/apt.14279] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
351 Peña-Rodríguez M, Vega-Magaña N, García-Benavides L, Zepeda-Nuño JS, Gutierrez-Silerio GY, González-Hernández LA, Andrade-Villanueva JF, Del Toro-Arreola S, Pereira-Suárez AL, Bueno-Topete MR. Butyrate administration strengthens the intestinal epithelium and improves intestinal dysbiosis in a cholestasis fibrosis model. J Appl Microbiol 2021. [PMID: 33982373 DOI: 10.1111/jam.15135] [Reference Citation Analysis]
352 Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis 2015;6:124-37. [PMID: 25954497 DOI: 10.1177/2040622315580069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
353 Bernsmeier C, Singanayagam A, Patel VC, Wendon J, Antoniades CG. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure. Immunotherapy. 2015;7:641-654. [PMID: 26065379 DOI: 10.2217/imt.15.27] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
354 Keryakos HKH, Mohammed AA, Higazi AM, Mahmoud EAM, Saad ZM. Serum and ascitic fluid interleukin-17 in spontaneous bacterial peritonitis in Egyptian patients with HCV-related liver cirrhosis. Curr Res Transl Med 2020;68:237-43. [PMID: 32620468 DOI: 10.1016/j.retram.2020.03.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]